CN1440419A - 治疗和预防细菌感染的化合物和方法 - Google Patents
治疗和预防细菌感染的化合物和方法 Download PDFInfo
- Publication number
- CN1440419A CN1440419A CN01812400A CN01812400A CN1440419A CN 1440419 A CN1440419 A CN 1440419A CN 01812400 A CN01812400 A CN 01812400A CN 01812400 A CN01812400 A CN 01812400A CN 1440419 A CN1440419 A CN 1440419A
- Authority
- CN
- China
- Prior art keywords
- ser
- asn
- lys
- leu
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002265 prevention Effects 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 46
- 208000035143 Bacterial infection Diseases 0.000 title abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 title description 8
- 239000003053 toxin Substances 0.000 claims abstract description 127
- 231100000765 toxin Toxicity 0.000 claims abstract description 127
- 229960005486 vaccine Drugs 0.000 claims abstract description 26
- 101710194807 Protective antigen Proteins 0.000 claims description 343
- 241000193738 Bacillus anthracis Species 0.000 claims description 73
- 230000008859 change Effects 0.000 claims description 50
- 230000015572 biosynthetic process Effects 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 14
- 230000008034 disappearance Effects 0.000 claims description 12
- 238000006384 oligomerization reaction Methods 0.000 claims description 8
- 230000009849 deactivation Effects 0.000 claims description 7
- 206010030113 Oedema Diseases 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 230000003313 weakening effect Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 1
- 108700012359 toxins Proteins 0.000 abstract description 114
- 239000003814 drug Substances 0.000 abstract description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 740
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 735
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 689
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 601
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 586
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 564
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 562
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 548
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 374
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 355
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 334
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 303
- 102220023256 rs387907547 Human genes 0.000 description 83
- 210000004027 cell Anatomy 0.000 description 70
- 102220023257 rs387907546 Human genes 0.000 description 67
- 238000012360 testing method Methods 0.000 description 46
- 102220023258 rs387907548 Human genes 0.000 description 41
- 230000000694 effects Effects 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 19
- 241000193155 Clostridium botulinum Species 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 241000193468 Clostridium perfringens Species 0.000 description 16
- 241001147796 [Clostridium] spiroforme Species 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 230000007423 decrease Effects 0.000 description 15
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 14
- FLLRAEJOLZPSMN-CIUDSAMLSA-N Glu-Asn-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FLLRAEJOLZPSMN-CIUDSAMLSA-N 0.000 description 14
- GMVCSRBOSIUTFC-FXQIFTODSA-N Glu-Ser-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMVCSRBOSIUTFC-FXQIFTODSA-N 0.000 description 14
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 14
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 14
- MDVZJYGNAGLPGJ-KKUMJFAQSA-N Leu-Asn-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MDVZJYGNAGLPGJ-KKUMJFAQSA-N 0.000 description 14
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 description 14
- XDMMOISUAHXXFD-SRVKXCTJSA-N Phe-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O XDMMOISUAHXXFD-SRVKXCTJSA-N 0.000 description 14
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 14
- 102220369447 c.1352G>A Human genes 0.000 description 14
- 108010050848 glycylleucine Proteins 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 108010077037 tyrosyl-tyrosyl-phenylalanine Proteins 0.000 description 14
- 241000193163 Clostridioides difficile Species 0.000 description 13
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 13
- 102220369446 c.1274G>A Human genes 0.000 description 13
- 102220369445 c.668T>C Human genes 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 241000193755 Bacillus cereus Species 0.000 description 12
- 230000035772 mutation Effects 0.000 description 11
- 231100000820 toxicity test Toxicity 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 10
- 229940065181 bacillus anthracis Drugs 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 241000193388 Bacillus thuringiensis Species 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229910052701 rubidium Inorganic materials 0.000 description 7
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 101710092462 Alpha-hemolysin Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000017854 proteolysis Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000032895 transmembrane transport Effects 0.000 description 6
- 108010021466 Mutant Proteins Proteins 0.000 description 5
- 102000008300 Mutant Proteins Human genes 0.000 description 5
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000000452 restraining effect Effects 0.000 description 5
- 239000009871 tenuigenin Substances 0.000 description 5
- 241000607528 Aeromonas hydrophila Species 0.000 description 4
- 101710197219 Alpha-toxin Proteins 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- 101710124951 Phospholipase C Proteins 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 239000002776 alpha toxin Substances 0.000 description 4
- 229940097012 bacillus thuringiensis Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004961 Furin Human genes 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 108010059712 Pronase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000022338 anthrax infection Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 231100000710 AB5 toxin Toxicity 0.000 description 2
- 101000585552 Bacillus anthracis Protective antigen Proteins 0.000 description 2
- 101500000959 Bacillus anthracis Protective antigen PA-20 Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 241000193466 Clostridium septicum Species 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 101800000585 Diphtheria toxin fragment A Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 108700005090 Lethal Genes Proteins 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 101710182532 Toxin a Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- GVRKWABULJAONN-VQVTYTSYSA-N Val-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVRKWABULJAONN-VQVTYTSYSA-N 0.000 description 2
- -1 Xie Ansuan Chemical compound 0.000 description 2
- 108010014387 aerolysin Proteins 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004020 intracellular membrane Anatomy 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101000953492 Homo sapiens Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102100037739 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- ZKVLEFBKBNUQHK-UHFFFAOYSA-N helium;molecular nitrogen;molecular oxygen Chemical compound [He].N#N.O=O ZKVLEFBKBNUQHK-UHFFFAOYSA-N 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 230000005525 hole transport Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004763 spore germination Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供孔-形成毒素的突变体形式。这些突变体毒素可用作预防细菌感染的疫苗。另外显性负突变体可作为治疗剂施用,以治疗细菌感染。
Description
有关联邦政府资助研究的声明
本发明由国家卫生协会津贴R37-AI22021和2T32-AI07410资助。政府享有由本发明所获得的某些权利。
发明背景
总的来说,本发明涉及治疗细菌感染,如炭疽感染的化合物和方法。
当作为生物战或生物恐怖主义的媒介时,炭疽(炭疽杆菌(Bacillus anthracis))病源媒介具有潜在的危险,这是由于雾化的炭疽杆菌(B.anthracis)孢子对哺乳动物,如人类,来说是致命的。由这种生物所产生的主要剧毒性因子是聚-D-谷氨酸荚膜和炭疽毒素(ATx)。所述的荚膜和毒素均有利于细菌的群集和免疫逃避。仅单独的Atx即可导致宿主死亡。接种抗毒素的疫苗可防止宿主被感染。
炭疽毒素是一种细菌毒素,称为A-B毒素。A-B毒素包括两个组成成分,A组分是毒素的酶活性部分,其催化在靶细胞内对胞浆的毒性作用。B组分结合于细胞受体,使A组分易于穿过细胞膜进入胞浆。
来自破伤风,肉毒梭菌,白喉和炭疽的A-B毒素的B组分全部在细胞膜上形成通道。假定这些通道可以作为A组分膜转运的导管。所述的炭疽毒素A和B组分作为不同的多肽,由细菌细胞中分泌出来。其它的A-B毒素作为单链多肽产生,或作为单独的链产生再在释放到细菌外之前组装到寡聚体毒素中。有两种可替换的炭疽毒素A亚基,分别称为水肿因子(EF)和致死因子(LF)。EF或LF与保护性抗原(PA)B亚基的非共价复合物分别称为水肿毒素和致死毒素。PA使EF和LF易于穿过细胞膜。
PA作为83 kDa的单体多肽分泌出来。单体PA与哺乳动物细胞表面受体结合,通过蛋白水解开裂。C-末端63 kDa片段(PA63)仍然与细胞相结合,N-末端的20 kDa(PA20)与PA63解离。这一蛋白水解切割与接下来的PA20解离赋予了PA63两个新的特性:(1)寡聚化成为称为前孔的、SDS可解离的环状七聚体结构的能力(2)与EF和LF结合的能力。包含PA63-EF,PA63-LF,或PA63-EF和PA63-LF的结合的寡聚物经胞吞并运输到酸性区室,在那里PA63前孔插入到细胞膜中形成孔。在孔形成过程中或形成后,EF和LF穿过胞内膜进入细胞质。EF是钙调蛋白-依赖的腺苷酸环化酶,其可保护细菌不受吞噬细胞的破坏。LF是一种金属蛋白酶,其可以杀死巨噬细胞或在低浓度下诱导巨噬细胞过量的产生细胞因子,其可能导致宿主死亡。
这一中毒途径的关键步骤是由PA形成孔。低pH引发PA63前孔向孔的转化。这一转化伴随可使所述的寡聚体由SDS可解离状态向抗SDS状态的转化并形成跨膜的14-链β桶。这些步骤对EF和LF穿越胞内膜进而进行毒性作用是必需的。
发明公开
第一方面本发明提供由两部分组成的形成孔的A-B毒素的B组分。所述的B组分带有突变,导致其孔形成能力受到抑制。在一个优选的实施方案中,这一突变导致在体内该蛋白的孔形成能力受到抑制。在另一个优选的实施例中,所述突变的B组分在体外和/或体内缺乏孔形成能力。在又一优选的实施方案中,所述的B组分是炭疽保护抗原(PA)。在再一优选的实施方案中所述的PA突变体具有与天然存在的PA蛋白(如SEQ ID No.:21;图13所示)存在至少80%,90%,95%或98%同一性的氨基酸序列,并且其具有下述的替换之一:K397A,K397D,K397C,K397Q,D425A,D425N,D425E,D425K,F427A,K397+D425K双突变体,K395D+K397D+D425K+D426K四重突变体,K397D+D425K+F427A三重突变体,F427A+ΔD2L2双突变体,K397D+F427A+ΔD2L2三重突变体,K397D+D425K+F427A+ΔD2L2四重突变体,F427D,或F427K。在另一优选的实施方案中,所述的PA突变体与SEQID Nos.:1-11和13-18(表1)中的任意序列具有序列同一性。其它优选的PA突变体包括第397位是除赖氨酸外的任意氨基酸残基的PA突变体(SEQ ID No.:19),第425位是除天冬氨酸外的任意氨基酸残基的PA突变体(SEQ ID No.:20),第427位是除苯丙氨酸外的任意氨基酸残基的PA突变体(SEQ ID No.:23),在结构域2(259-487位残基)存在突变的PA突变体。再有其它优选的突变体B组分包括一个或多个列于表6的替换或相应于PA结构域2存在突变的艰难梭菌(Clostridium difficile),产气荚膜梭菌(C.perfringens),螺状梭菌(C.spiroforme),肉毒梭菌(C.botulinum),蜡状芽孢杆菌(Bacillus cereus)或苏云金芽孢杆菌(B.Thuringiensis)毒素。上述突变体B组分的片段也包含在本发明的范围内,其与天然存在的相应毒素的B组分相比具有降低的孔形成能力。具有本发明的突变体B组分或其片段与另一多肽或蛋白共价结合的融合蛋白也包含在本发明的范围内。特别地从本发明的第一方面排除出去的是PA的302-325位氨基酸(D2L2环)缺失。
在本发明的第二方面中涉及含有第一方面中突变体B组分或ΔD2L2 PA(第302-325位氨基酸缺失的PA突变体)或其片段,以及在制药学上可接受的载体的疫苗组合物。在一个优选的实施方案中,所述的疫苗可以能通过化学或物理的方法灭活。
第三方面,本发明涉及防止或治疗哺乳动物,如人细菌感染的方法。这一方法包括对所述哺乳动物施用本发明第二方面中所述的疫苗。在一个优选的实施方案中,所述的疫苗与制药学上合适的载体或佐剂一起施用。所述的疫苗可通过口服,肌肉内,静脉内,皮下,或通过吸入的方式施用,或者通过其它足以提供预防或治疗细菌感染的途径施用。在另一优选的实施方案中,通过施用包含突变的炭疽保护抗原的疫苗以预防或治疗炭疽感染。
第四方面,本发明涉及由两组分组成的孔形成A-B毒素的突变体B组分。所述的突变体B组分存在导致孔形成能力受到抑制。所述的突变体B组分也体内和/体外抑制天然存在的相应毒素的B组分的孔形成能力。在一个优选的实施方案中,这一突变导致体内该蛋白的孔形成能力受到抑制。在另一优选的实施方案中,所述的突变体B组分在体内和/或体外缺乏孔形成能力。在又一优选的实施方案中所述的B组分是炭疽保护性抗原(PA)。所述的突变体B组分可以与相应毒素的A组分结合。例如,某种PA突变体可以与致死因子或水肿因子A组分相结合。所述的突变体B组分可与天然存在的B组分竞争结合于哺乳动物细胞表面的受体。所述的突变体B组分也可以与天然存在的相应毒素的B组分相结合。这种突变体B组分可以与天然存在的B组分寡聚化形成复合物以降低孔形成能力。在一个优选的实施方案中,所述的复合物缺乏形成孔并进一步使A组分(例如EF或LF)穿过细胞膜运输到细胞质的能力。
在第四方面的一个优选的实施方案中,所述的突变体PA具有与天然存在的PA蛋白(例如SEQ ID No.21;图13)存在至少80%,90%,95%,或98%同一性的氨基酸序列,并存在下述的替换之一:K397D+D425K双突变体,ΔD2L2(其中PA的第302-325位残基缺失),K395D+K397D+D425K+D426K四重突变体,D425K,F427A,K397D+D425K+F427A三重突变体,F427A+ΔD2L2双突变体,K397D+F427A+ΔD2L2三重突变体,K397D+D425K+F427A+ΔD2L2四重突变体,F427D,或F427K。在另一优选的实施方案中,所述的PA突变体与SEQ ID Nos.:8-18(表1)中的任意一项具有序列同一性。在又一优选的实施方案中,天然存在的PA中第395,397,425,426位氨基酸,或其结合发生突变。在另一实施方案中,存在于PA结构域2中的残基发生突变。在又一优选的实施方案中,所述的PA的D2L2环中或另一由两组分构成的孔形成A-B毒素的B组分的相应区域具有至少2,至少10或至少20个氨基酸残基缺失。所述的突变体具有全部或部分D2L2环缺失以及该环的N-或C-末端的氨基酸缺失。再有其它优选的突变体B组分包括一个或多个列于表6的替换或相应于PA结构域2存在突变的艰难梭菌(Clostridium difficile),产气荚膜梭菌(C.perfringens),螺状梭菌(C.spiroforme),肉毒梭菌(C.botulinum),蜡状芽孢杆菌(Bacillus cereus)或苏云金芽孢杆菌(B.Thuringiensis)毒素。上述突变体B组分的片段也包含在本发明的范围内,其与天然存在的相应毒素的B组分相比具有降低的孔形成能力。由本发明的突变体B组分或其片段与另一多肽或蛋白共价结合的融合蛋白也包含在本发明的范围内。
第五方面本发明涉及预防和治疗哺乳动物,如人的细菌感染的方法。该方法包括对哺乳动物施用能抑制天然存在的B组分的孔形成能力的上述第四方面的突变体B组分或其片段。在一个实施方案中,上述第四方面的PA突变体或其片段施用于已暴露于炭疽杆菌(B.anthracis)孢子的哺乳动物以预防或治疗炭疽感染。在另一实施方案中,所述的蛋白作为预防性施用。在一个优选的实施方案中,所述的突变体B组分与药学上适合的载体一起施用。所述的疫苗可通过口服,肌肉内,静脉内,皮下,或通过吸入的方式施用,或者通过其它足以提供预防或治疗炭疽菌感染的剂量的途径施用。在一个实施方案中,所述的方法还包括对哺乳动物施用抗-B组分抗体,如可与天然存在的B组分结合,但不与显性负B组分结合的抗体。在一个特定的实施方案中,所述的抗体可与天然存在的PA结合,但不与显性负PA突变体结合。
第六方面,本发明涉及编码上述第一或四方面的突变体B组分(如PA突变体)的核酸。
第七方面,本发明涉及具有上述第六方面的核酸的载体。
第八方面,本发明涉及可与天然存在的PA或列于表1的PA突变体蛋白特异结合的纯化抗体。在一个实施方案中,所述的抗体与PA蛋白的D2L2环、K397,D425,D426,或F427结合。所述的抗体可以是单克隆抗体也可以是多克隆抗体。在相关的方面,本发明涉及纯化的抗体,其可以比结合于相应毒素的本发明的B组分更强的亲和力,特异性地与天然存在的由两个组分组成的孔形成A-B毒素的B组分结合。另一相关的方面中,本发明涉及纯化的抗体,其可以比结合于天然存在的由两个组分组成的孔形成A-B毒素的B组分更强的亲和力,特异性地与相应毒素的本发明的B组分结合。
在第一和第四方面的一个实施方案中,特异地排除那些具有唯一的替换,定位于跨膜孔疏水表面的半胱氨酸残基突变的那些PA分子。在这些方面的另一实施方案中,那些定位于跨膜孔疏水表面的氨基酸残基突变为其唯一替换的PA分子被特异排除在外。在一个实施方案中,特异地排除在所述第一和第四方面之外的是那些在天然存在的PA分子中Glu302,His304,Asn306,Glu308,His310,Ser312,Phe313,Phe314,Asp315,Gly317,Ser319,Ser321,Gly323,或Ser325处的突变作为唯一替换的PA分子。在这些方面的一个实施方案中,特异地排除了以在D2L2环的氨基酸序列中存在的突变作为其唯一替换的PA分子。在另一实施方案中,在形成跨膜孔的氨基酸中的突变或缺失作为其唯一替换的PA分子被排除在外。在又一实施方案中,特异地排除在外的是ΔD2L2PA。在又一实施方案中,特异地被排除在这些方面之一之外的是具有C-末端63 kDA胰蛋白酶片段(PA63)且以形成跨膜孔的氨基酸中的突变作为其唯一替换的PA分子。在其它不同的实施方案中,被特异地排除在这些方面之一之外的是具有相应于其它被排除在外的PA突变体的突变的,其它由两组分组成的孔形成A-B毒素。在这些方面的不同实施方案中,所述的突变体B组分,以比天然存在的B组分与来自相同A-B毒素的其它天然存在的分子相结合更高平衡常数(即更高的亲和力)与来自天然存在的相同A-B毒素的B组分结合。在优选的实施方案中,所述的突变PA蛋白以,比天然存在的PA与其它天然存在的PA分子的结合高出至少2,5,10,或20倍的亲和力与天然存在的PA分子结合。
应当理解,除炭疽毒素外的其它孔形成毒素也可在本发明的化合物和方法中使用。例如孔形成毒素,如其它具有抑制所述毒素孔形成能力的突变(点突变或缺失突变),或抑制天然存在毒素的孔形成能力突变的A-B毒素均包含在本发明的范围内。所述的带有这些突变的孔形成毒素可用于本发明的疫苗组合物和方法中以预防或治疗所述毒素的病源媒介的感染。
在不对本发明作任何限制的前提下,也可以使用其它由两组分构成的A-B毒素;异源寡聚体毒素(AB5毒素),如霍乱毒素;或其它单一的多肽A-B毒素,如破伤风,肉毒梭菌,或白喉毒素。其它可以使用的毒素包括来自金黄色葡萄球菌(Staphylococcus aureus)的α-溶血素,来自嗜水气单胞菌(Aeromonas hydrophila)的气单胞菌溶素,来自败毒梭菌(Clostridium septicum)的α-毒素,和来自铜绿假单胞菌(Pseudomonas aeruginosa)的细胞毒素。本发明还涉及其它孔形成毒素,如胆固醇依赖性的溶细胞素,六聚体毒素,或七聚体毒素。六聚体和七聚体毒素的例子包括与葡萄球菌相关的α-毒素。在一个实施方案中,来自幽门螺旋杆菌(Helicobacter pylori)的VacA毒素的缺失突变被特异地排除在外。
“突变”指在核酸序列中的替换,由此由核酸序列编码的氨基酸序列与天然存在的序列相比有至少一个氨基酸的替换。所述的突变可以是,但不限于插入,缺失,移码突变或缺失突变。
“孔形成毒素”是指形成跨膜含水孔的毒素。
“孔形成A-B毒素”指具有两个功能组分的孔形成毒素;一个组分(B)在所述宿主细胞屏障膜中形成孔,另一个(A)组分穿过所述的膜屏障并酶促修饰宿主细胞中的特异细胞内底物。
“由两组分组成的孔形成A-B毒素的”是指孔形成A-B毒素,其中所述孔形成毒素的A和B组分分别存在于独立的蛋白中,并在宿主细胞的中毒过程中相互作用。由两个组分组成的毒素的例子是炭疽毒素。
″B组分″是指孔形成A-B毒素的组件,其与特异的宿主细胞表面受体结合,与所述毒素的A组分相互作用,并辅助A组分向所述细胞的内在化。许多B组分,如PA也可形成跨膜的孔。
″保护性抗原(PA)″是指具有此处所述的炭疽PA多肽的生物活性的60%,70%,80%,或90%的至少之一多肽。所述的多肽可由Vodkin等(Cell 34:693-697,1983)中报道的PA基因编码。所述的多肽可以具有与Miller等(Biochemistry 38(32):10432-10441,1999)(SEQ IDNo.:21)描述的野生型PA,或其它任何来自炭疽杆菌(Bacillusanthracis)的天然存在的PA多肽相同的特性。所述的PA多肽可以在异源宿主如大肠杆菌或枯草芽孢杆菌中克隆和表达。应当理解具有此处所述的炭疽PA特性的同源物或类似物也可用在本发明的方法中。
″PA63″指由PA多肽经蛋白水解切除20 kDa N-末端节段所得的羧基末端部分。PA63形成七聚体的前孔并与两个可替换的A组分,水肿因子(EF)和致命因子(LF)结合。所述的整个复合物运输到内体,在那里PA63插入到细胞膜形成跨膜孔并将EF和LF转移到宿主细胞的细胞质中。
“跨膜孔”是指跨越细胞膜的含水通道。例如所述的跨膜孔可以是β-筒通道,其是通过替换PA63的亲水和疏水残基,以使疏水残基形成所述筒的外膜表面,亲水残基朝向跨越宿主细胞细胞膜的孔的含水腔。
“跨膜孔的亲水表面”是指朝向跨越宿主细胞细胞膜的孔的含水腔的PA的氨基酸。
“形成跨膜孔的氨基酸”是指定位于跨膜孔β-筒通道的PA的氨基酸。
″D2L2环″是指连接此处所述的PA多肽的2β2和2β3链和PA63多肽的两亲环。
″抑制孔形成能力″是指降低膜中孔形成的量或降低运输到宿主细胞细胞质中的A组分(如EF或LF)的速率和数量。这种孔形成或毒素转移的降低与此处所述的在细胞表面转移的活性LFnDTA毒性、铷释放分析下降正相关,也可通过上述试验预测出。这一下降的活性可与下述情况联系起来:在细胞表面转移试验中,放射性标记的配体数量下降;在LFnDTA毒性试验中,由于配体转移到细胞内使蛋白合成的抑制的下降;或在铷释放分析试验中,由细胞释放的放射性标记的离子的下降。另外这一下降的活性可与由于毒性配基转移到细胞内使得毒性下降联系起来。在一个优选的实施方案中,孔形成或A组分转移的下降至少是相对于天然存在的相应毒素的B组分的20%,更优选至少40%,最优选至少80%。在另一优选的实施方案中,孔形成或PA突变体EF或LF转移的下降是相对于天然存在的PA63的20%,更优选至少40%,最优选至少80%。
″缺乏孔形成能力″是指不能在膜中形成显著数量的孔,或不能将显著数量的EF或LF转移到宿主细胞的细胞质中。这种缺乏显著的孔形成或毒素转移能力与此处所述的在细胞表面运输,LFnDTA毒性,或铷释放试验中显著活性的缺乏正相关,也可通过上述的实验预测。在一个优选的实施方案中所形成的孔的数量和毒素转移的数量比在没有PA的对照试验中的少5倍。更优选所述的数量比在没有PA的对照试验中的少2倍。
“片段”是指具有与PA突变体中的相应区域同一的连续氨基酸区域的多肽。所述的片段与天然存在的PA相比或具有降低的孔形成或毒素转移的能力。所述的片段也可以抑制天然存在的PA的孔形成能力。这种孔形成或毒素转移的降低与此处所述的在细胞表面转移的活性LFnDTA毒性、铷释放试验中的下降正相关,也可通过上述试验预测出。这一下降的活性可与下述情况联系起来:在细胞表面转移试验中,放射性标记的配体数量下降;在LFnDTA毒性试验中,由于配体转移到细胞内使蛋白合成的抑制的下降;或在铷释放分析试验中,由细胞释放的放射性标记的离子的下降。在一个优选的实施方案中,孔形成或EF或LF转移的下降至少是相对于天然存在的PA63的20%。更优选至少40%,最优选至少80%。对天然存在的PA的孔形成能力的抑制与上述与单独的天然存在的PA相比,用等摩尔的天然存在的PA和PA片段的试验中的活性下降正相关,也可通过上述的试验预测出。在一个优选的实施方案中,与仅用天然存在的PA相比,所述的下降是至少20,40,60,80,或99%。所期望的是,所述的片段是免疫原性的且能够诱导针对天然存在的PA的保护性抗体产生。在另一优选的实施方案中,如实施例9所述对哺乳动物施用所述的片段,在至少1个月,优选3个月,最优选6个月的时间内预防或减少炭疽感染。可能的片段的例子包括PA突变体的C-末端63kD胰蛋白酶片段或具有形成跨膜孔的氨基酸缺失的PA突变体。
“经纯化的抗体”是指重量至少占60%的去除了下述物质的抗体,所述的物质是指上述抗体在天然状态下与之结合的蛋白和天然存在的有机分子。预期上述制备物中的抗体至少占重量的75%,更优选90%,最优选99%。经纯化的抗体可以,例如利用重组蛋白或保守组分肽以标准的方法通过亲和层析获得。
“特异结合”是指一种抗体识别并结合于天然状态下包括蛋白的样品,例如生物样品中的野生型PA或PA突变体,但基本上不识别、结合非PA分子。优选的抗体特异结合于列于表1#1-18中的任何PA突变体。其它优选的抗体以与列于表1的一种或多种突变体结合高出至少2,5,10,或20倍的亲和力与野生型的PA结合。
序列同一性典型地使用序列分析软件(例如Sequence AnalysisSoftware Package of the Genetics Computer Group,Universityof Wisconsin Biotechnology Center,1710 University Avenue,Madison,WI 53705),以其所特有的缺省参数进行测定。这种软件通过赋予不同的取代,缺失,和其它修饰以不同程度的同源性来比较序列相似性。保守取代典型地包括下述组中的取代:甘氨酸,丙氨酸,缬氨酸,异亮氨酸,亮氨酸;天冬氨酸,谷氨酸,天冬酰胺,谷氨酰胺;丝氨酸,苏氨酸;赖氨酸,精氨酸;和苯丙氨酸,酪氨酸。
本发明的其它特征和有益之处将通过下述的详细描述予以说明。
附图说明
图1是ATx毒素中毒途径的图示说明。Atx中的PA组分与哺乳动物细胞表面的受体结合,并如上所述向胞质溶胶中运送所述毒素的酶促A组分,水肿因子(EF)和致命因子(LF)。
图2A是SDS-PAGE凝胶图,表明缺口PA突变体蛋白的形成和由野生型,K397Q,和ΔD2L2 PA形成抗-SDS的寡聚体。图2B是天然的凝胶表明由野生型,K397A,和ΔD2L2 PA形成前孔。
图3是表明与野生型,K397A,或D425A PA一起培养后,与无PA的对照相比,86RB负载细胞释放86Rb的量的柱形图。
图4A是表明与野生型,K397A,或D425APA一起培养的细胞所结合的相似水平的35S-LFn(LF的PA结合结构域N-末端1-255氨基酸)。图4B与野生型PA相比由K397A或D425A PA介导的35S-LFn向细胞内转移的减少。
图5是表明在LFnDTA毒性试验中,通过与野生型,K397A,或D425APA共同培养后,不溶性的TCA组分(蛋白组分)中3H-Leu的百分比。包含与白喉毒素A链融合的LFn的LFnDTA转运到细胞中使得EF-2核糖基化,导致蛋白合成受到抑制,在蛋白组分中3H-Leu的量下降。
图6A是表明35S-LFn对与野生型,ΔD2L2,双突变体K397D+D425K,或野生型和ΔD2L2或K397D+D425K PA的混合物一起培养的细胞的相似结合性的柱形图。图6B是表明由ΔD2L2或K397D+D425K PA,野生型PA-介导的35S LFn转运的下降的柱形图。
图7表明与单独的野生型PA相比,与ΔD2L2或K397D+D425K PA和野生型的PA一起培养后,在TCA不溶性组分中较高百分比的3H-Leu。这一结果与LFnDTA毒性试验中由野生型PA-介导的蛋白合成的抑制作用的降低相应。
图8A表明LFnDTA毒性试验中由野生型PA-介导的蛋白合成的抑制作用的降低。突变PA蛋白浓度的升高减少了由野生型PA-介导的3H-Leu摄入到TCA不溶性组分中的抑制作用。图8B表明与列于图8A中的突变体需要量相比,需要更大量的相对于野生型PA的PA-SSR以降低野生型PA-介导的3H-Leu摄入的抑制。
图9表明在LFnDTA毒性试验中,野生型PA-介导的蛋白合成的抑制的降低是由于存在显性负PA突变体浓度的升高。显示在该图中的是显性负突变体K397D+D425K(□),ΔD2L2(■),F427A(○),D425K(△),和K397D(◇)和对照突变体SSSR(◆)的效果。
图10是表明在LFnDTA毒性试验中,野生型PA-介导的蛋白合成的抑制的降低是由于出现下述的一种显性负PA突变体浓度升高:K397D+D425K(■),F427A+ΔD2L2(□),K397D+D425K+F427A(○),和K397D+F427A+ΔD2L2(▲)。
图11是表明野生型PA与突变体PA(K397D+D425K,ΔD2L2,F427A,或D425K)混合形成异源七聚体,然后用胰蛋白酶裂解PA分子而使蛋白合成受到抑制的柱形图。以1∶1混合的相应突变体与野生型同源七聚体混合物对蛋白合成的抑制也进行了测定。
图12是表明显性负突变体K397D+D425K,ΔD2L2,F427A,和D425K对低-pH引发的35S LFN穿越质膜的作用的柱形图。所示的结果是三次实验的平均±SEM。
图13是用于此处所述试验的野生型PA蛋白的氨基酸序列(SEQ IDNo.:21)。此处所述的PA突变体蛋白均基于该野生型序列。
图14是编码用于此处所述试验的野生型PA蛋白的多核苷酸序列(SEQ ID No.:22)。
图15是PA与其它由两个组分组成且具有ADP核糖基转移酶活性的A-B毒素的氨基酸序列对比。此处列出所述的来自梭状芽孢杆菌艰难梭菌(Clostridium difficile)(″cdADPRT″),产气荚膜梭菌(C.perfringens)(″cpiota″),螺状梭菌(C.spiroforme)(″csiota′),和肉毒梭菌(C.botulinum)(″cbc2″)的毒素的氨基酸序列。产气荚膜梭菌(C.perfringens)和螺状梭菌(C.spiroforme)毒素通常是指ι(iota)毒素,而肉毒梭菌毒素是指C2。另外,上述对比包括由蜡状芽孢杆菌(Bacillus cereus)(″VIP1″)产生的毒素,该毒素通常被认为是VIP是植物杀虫蛋白。
图16是PA的氨基酸序列与来自艰难梭菌(Clostridiumdifficile)(″cdADPRT″),产气荚膜梭菌(C.perfringens)(″cpiota″),螺状梭菌(C.spiroforme)(″csiota′),和肉毒梭菌(C.botulinum)(″cbc2″)的毒素的氨基酸序列的对比。这一对比显示了所述毒素的全序列。
发明详述
我们发现了一种阻止A-B毒素感染产生细菌的方法。由此,本发明提供用作对特定细菌感染,包括炭疽和坏疽感染解毒剂的组合物。由于该组合物是安全且具有免疫原性的,它也可以用作疫苗。
对炭疽pA多突变体进行构建,表达,纯化,并通过试验确定其是否具有比野生型PA减弱的活性。具体地说是试验这些突变体结合PA配体和受体的能力;形成前孔,抗SDS-寡聚体,和孔的能力;和运送配体穿越细胞膜的能力。基于PA的x-射线结构预测将突变的残基设计到PA前孔的腔中。具有减弱的或检测不到的在膜上形成孔的能力的PA突变体或其片段可用作疫苗以诱导预防炭疽感染的保护性抗体。另外,这些突变体比野生型PA更有效地治疗炭疽感染,这是由于它们具有减弱的转移由受感染的哺乳动物中的炭疽杆菌(Bacillusanthracis)的分泌的EF和LF的能力。
研究这些点突变体,和先前报道的缺少结构域2(ΔD2L2)的跨膜环2中第302-325位残基的缺失突变体(Miller等,Biochemistry38:10432-10441,1999)的特性,以进一步确定是否他们可以通过减少野生型PA的孔形成而作为显性负抑制剂。这一抑制可能是由于突变体与配体或受体结合,以使得很少的分子与野生型PA结合。所述的突变体也可以与野生型PA形成寡聚体,其具有减弱的或检测不到的形成孔及转运配体的能力。如上所述,显性负PA突变体及其片段可用作疫苗以引发预防或治疗炭疽感染的保护性抗体。另外,具有显性负活性的突变体或其片段可以通过抑制受感染的哺乳动物中的炭疽杆菌(Bacillus anthracis)分泌的PA的活性作为治疗炭疽感染的治疗剂。因为显性负突变体可以诱导保护性抗体产生并抑制感染细菌产生的PA的活性,其可作为治疗受炭疽感染、或有受炭疽感染危险的个体的组合疫苗/治疗剂。除了需要尽快消除毒素的作用,对暴露于雾化的炭疽杆菌(B.anthracis)孢子的个体进行预防接种也同样重要。这种预防接种对抵抗由于能够在体内长期停留(至少一个月)的孢子萌发而引起的延迟收缩至关重要。
在这一研究中,鉴定了几种缺乏孔形成能力和转运配体能力的PA突变体,它们是潜在的预防和治疗炭疽感染的疫苗(表1)。突变体#1-12能够由蛋白水解激活形成易于SDS解离的PA63前孔状态,并结合于细胞受体EF,和LF。一些突变体阻止由前孔到抗SDS状态的转换(表1)。这些突变体(K397A,K397C,K397D,D425A,D425N,D425KD425E,D425K,K397D+D425K,和K395D+K397D+D425K+D426K)在孔形成和膜运输方面也存在缺陷。其它种类的突变体(ΔD2L2 PA,K397Q,和F427A)形成抗SDS寡聚体,但不经过膜插入和孔形成。这些结果是出乎预料的。
表1.保护性抗原突变体的活性
突变体 | SEQ ID No. | 突变 | 形成SDS-抗性寡聚体? | 形成通道? | 显性阴性? |
1 | 1 | K397A | 否 | 否 | 否 |
2 | 2 | K397D | 否 | 否 | 否 |
3 | 3 | K397C | 否 | 否 | 否 |
4 | 4 | K397Q | 是 | 否 | 否 |
5 | 5 | D425A | 否 | 否 | 否 |
6 | 6 | D425N | 否 | 否 | 未确定 |
7 | 7 | D425E | 否 | 否 | 否 |
8 | 8 | D425K | 否 | 否 | 是 |
9 | 9 | F427A | 是 | 否 | 是 |
10 | 10 | K397D+D425K | 否 | 否 | 是 |
11 | 11 | K395D+K397D+D425K+D426K | 否 | 否 | 是 |
12 | 12 | ΔD2L2 | 是 | 否 | 是 |
13 | 13 | K397D+D425K+F427A | 未确定 | 未确定 | 是 |
14 | 14 | F427A+ΔD2L2 | 未确定 | 未确定 | 是 |
15 | 15 | K397D+F427A+ΔD2L2 | 未确定 | 未确定 | 是 |
16 | 16 | K397D+D425K+F427A+ΔD2L2 | 未确定 | 未确定 | 是 |
17 | 17 | F427D | 未确定 | 未确定 | 是 |
18 | 18 | F427K | 未确定 | 未确定 | 是 |
这些PA突变体是如实施例1所述构建的。
突变体(ΔD2L2,K397D+D425K双突变体,K395D+K397D+D425K+D426K四重突变体,D425K,F427A,K397D+D425K+F427A三重突变体,F427A+ΔD2L2双突变体,K397D+F427A+ΔD2L2三重突变体,K397D+D425K+F427A+ΔD2L2四重突变体,F427D,和F427K)中的几种抑制野生型PA-介导的配体跨膜转运。ΔD2L2和K397D+D425K PA突变体可与野生型PA形成寡聚体,其不能转运配体。这些结果是出乎预料的。在七聚体前孔内存在这些突变体中的单一分子即足以阻止孔转化。这种阻止由野生型PA的孔形成的能力,与和野生型PA竞争结合细胞受体,并从循环中去除EF和LF的能力相偶联使得这些突变体在治疗和预防炭疽感染方面特别引人关注。
PA中的其它残基突变也可抑制孔的形成和产生显性负活性。例如,可与带电的侧链Lys397或Asp425产生静电相互作用的残基也是PA孔形成中所需的,这些残基中的一个或其组合的突变也可抑制孔的形成并产生显性负活性。另外,小部分302-325 D2L2环缺失或该环的侧翼氨基酸缺失,以及全部或部分302-325区域缺失能够产生这种结果。
获得具有检测不到的形成孔或转运配体能力的PA突变体,及可作为野生型PA显性负抑制剂的突变体的能力表明在其它毒素中也可以获得类似的突变体,如来自金黄色葡萄球菌(Staphylococcus aureus)的α-溶血素,来自嗜水气单胞菌(Aeromonas hydrophila)的气单胞菌溶素,来自败毒梭菌(Clostridium septicum)的α-毒素,来自铜绿假单胞菌(Pseudomonas aeruginosa)的细胞毒素,异源寡聚体毒素(AB5毒素)或破伤风,肉毒梭菌或白喉毒素的B组分。另外,这些结果强调显示了鉴定许多其它寡聚毒性因子,范围从毒素到粘附素的显性负形式的可能性。
在炭疽毒素和其它装配过程在与胞外环境的相互作用中出现的寡聚体系统中,外源添加的突变体亚单位可以大体上并入最终的结构中,提高了这些亚单位用于治疗的可能性。全身炭疽,尽管罕见作为天然疾病,但作为生物战和恐怖主义的试剂则具有威胁性,显性负PA看来是其中最有效的治疗剂。假定施用的显性负PA与炭疽杆菌(B.anthracis)在体内产生的野生型PA任意混合,所述的蛋白将在细胞上共装配以形成非活性的终端复合物,由此阻止LF和EF的作用。除对明显的症状进行预防外,显性负突变体还可以保护专职的吞噬细胞不受损害,由此帮助宿主根除所述感染。向人体注射野生型PA后没有观察到明显的副作用,由此该蛋白的突变体灭活形式将不会造成危害。
显性负PA还可以用作抗炭疽的新疫苗的基础。如其名称意味着的那样,PA诱导针对炭疽的保护性抗体,事实上美国目前该疫苗的主要免疫原是得到许可的。在Fisher大鼠中,此处所述的ΔD2L2,K397D+D425K,和F427A突变体显示极少或没有有关相对于野生型PA的致免疫性降低。我们还发现突变体出乎预料的为显性负,因此以突变体比野生型PA 0.25:1的比率施用于大鼠模型不会引起可检测到症状的炭疽感染。考虑用纯化的野生型PA作为目前得到许可的疫苗的替代,如果PA的显性负形式证明可有效地进行治疗,其也可以完成这一任务,排除了发展两种几乎相同的药剂的需要。
下述的实施例用来说明本发明。它们不以任何形式对本发明进行限制。除非另外提及,K397A和D425A PA突变体的数据作为获得列于表1的PA突变体号1-12的数据的代表。
实施例1:一般方法
细胞培养,培养基和化学药品
中国仓鼠卵巢-K1(CHO-K1)由美国典型培养物保藏中心获得。所述的细胞在添加了10%牛血清,500单位/mL青霉素G,2mM L-谷氨酰胺和500单位/mL链霉素硫酸盐的HAM′s F-12中生长,并于CO2含量5%的潮湿空气中维持。在进行试验前的16-18小时将细胞接种在24-或96-孔微滴定板(Costar,Cambridge,MA)。除非特别说明,所有用于细胞培养的培养基均由Gibco BRL获得。除非特别说明所有的化学药品均由Sigma化学试剂公司获得。
PA蛋白的构建和纯化
所述的不包含PA的第302-325位氨基酸的ΔD2L2 PA突变体,如上所述进行表达和纯化(Miller等,Biochemistry 38:10432-10441,1999)。表1中#1-11点突变是用QuickChange定点诱变方法,依照制造商所述的方法进行的(Stratagene,La Jolla,CA)。Miller等(见上)编码野生型PA的质粒用作模板。将点突变体克隆到pET22-b(+)(Novagen)表达载体中,转化到BL21(DE3)(Novagen)中表达。所述的点突变体依上述进行表达、纯化(Miller,1999)。简要地说,培养物在LB培养基中于37℃下培养至A600为1.0。添加β-D-异丙基硫代半乳吡喃糖苷(β-D-isopropylthiogalactopyranoside)至1mM以诱导重组蛋白表达。诱导后所述细胞在30℃下继续培养3小时,然后以8000xg离心10分钟收集细胞。
所述的蛋白通过渗透休克从胞质中释放出来。将所述细胞悬浮于20mM Tris-HCl,pH8.0,30%葡萄糖和1mM EDTA在室温下温育10分钟并伴随连续的搅拌。再次通过离心收集细胞,悬浮于含20mM苄脒的5mM MgSO4中,在4℃下温育10分钟并伴随连续的搅拌。再次通过8000xg离心使细胞成颗粒状,轻轻倒出提取出的perplasmic。加入Tris-HCL pH8.0至终浓度为20mM,将全部样品上到Q-sepharoseHP柱中。用缓冲液A(20mM Tris,pH8.0)从柱中洗去未结合的蛋白。结合的蛋白用0%-25%线性梯度的缓冲液B(20mM Tris,pH8.0,1M NaCl)洗脱。浓缩含有PA的组分,用含有缓冲液A的pd-10柱(Amersham-Pharmacia)交换上述缓冲液。含有PA的洗脱物加到Mono-Q柱用0-25%梯度的缓冲液B洗脱。通过SDS-PAGE分析含有PA的组分并将其贮存于-80℃。用Bio-Rad蛋白分析试剂盒根据制造商所述的方法确定蛋白的浓度。所有的液相色谱均使用AKTA-净化液相色谱系统(Amersham-Pharmacia)。
其它的PA突变体(表1中#13-18)也类似地进行表达和纯化。
PA的蛋白水解激活
胰蛋白酶用于蛋白水解裂解PA83成为缺口PA(nPA)。将PA稀释至浓度为0.5mg/ml用于前孔-形成试验或0.2mg/ml用于其它试验。添加胰蛋白酶至终胰蛋白酶浓度比PA的比率为1∶1,000(w∶w),所述的混合物于室温下温育20分钟,然后用超过大豆胰蛋白酶抑制剂10摩尔的剂量抑制胰蛋白酶的作用。
细胞表面转运试验
如上所述用细胞表面转运试验测定PA-介导的放射性标记的LFn(LF的PA结合结构域N-末端1-255氨基酸)的转运(Wesche等,Biochemistry37:15737,1998)。简要地说,nPA(2×10-8M)先结合于CHO细胞,然后与结合于细胞表面的PA63结合的35SLFn结合。去除过量的LFn,洗细胞,并在37℃下使细胞经受pH5.0脉冲。所述的低pH模拟内体的酸化作用并导致PA-介导的LFn转运转过质膜进入细胞。将所述的样品用链霉蛋白酶处理,所述蛋白酶可以通过蛋白水解降解胞外的35S-LFn,但不能降解已转运到细胞内的35S-LFn。清洗所述细胞并进行细胞溶解。为确定与细胞结合的35S-LFn的总量,一些细胞不用链霉蛋白酶处理。细胞溶解后,用闪烁计数器确定在上清液中的35S-LFn。如下所述计算转运的百分比:(经保护不受链霉蛋白酶影响的DPM)/(与细胞结合的DPM)×100=%已转运的。
利用在经胰蛋白酶处理前等摩尔结合的突变体和野生型PA,并且在加入细胞前将其稀释到2×10-8M PA(每种蛋白1×10-8M)也进行了上述试验,以确定是否突变体PA蛋白抑制野生型的PA对LFn的转运。当1×10-8M浓度的PA用作对照时,与上述用2×10-8M野生型PA进行的试验相比,转运效率仅稍稍受PA中的落差的影响,这表明任何转运和结合的降低都不是野生型PA浓度落差的结果。
蛋白合成的抑制
蛋白合成的LFnDTA抑制是用作测定PA-介导将配体转运到细胞内的另一种方法(Milne等,Mol.Microbiol.15:66,1995)。为对列于表1中的PA突变体#1-12进行分析,在添加PA蛋白前16小时,将CHO-K1细胞置于2.5×104细胞/孔的96孔板中。在存在1×10-8M LFnDTA的情况下,将PA83(1×10-12M到1×10-7M)与细胞一起培养4小时。去除所述的培养基更换为添加了1 mCi/ml3H-Leu的无亮氨酸的HAM′s F-12培养基。培养1小时后用冰冷的PBS接着用冰冷的三氯醋酸(10%)沉淀蛋白。掺入TCA不溶物质中的3H-leu的数量用闪烁计数器确定,并作为新合成的蛋白的量的尺度。
在这一实验中还测试了突变体PA蛋白的以证明其是否减轻野生型PA-介导的对3H-leu摄入的抑制。将10×10-9M野生型PA与1×10-8MLFnDTA添加到CHO细胞中。加入递增量的突变体之一。将所述的细胞与毒素一起培养4小时,如上所述加工样品。
类似地对列于图9中的PA突变体进行试验。在LFN-DTA(100pM)及不同量的单独的PA突变体(K397D+D425K,ΔD2L2,F427A,D425K,K397D,或SSSR)存在下,CHO-K1细胞(2.5×104细胞/孔)与野生型PA(100pM)在96-孔板中于37℃下培养18小时。去除所述的培养基更换为添加了1μCi/ml 3H-Leu的无亮氨酸HAM F-12培养基。37℃培养1小时后用冰冷的PBS及冰冷的三氯醋酸(TCA)(10%)洗细胞。测定掺入到TCA-沉淀物中的3H-leu的量,其表明在不存在PA的情况下掺入的百分比。在所选择的野生型PA和LFnDTA浓度下,在不存在突变体PA(虚线)的情况下,蛋白合成受到约90%的抑制。报道了三次试验±SEM的平均值。在开始培养4小时而非18的情况下所观察到的结果是类似的。列于图10的K397D+D425K+F427A,F427A+ΔD2L2,和K397D+F427A+ΔD2L2PA突变体也进行了类似的试验。
将野生型异源七聚体和突变体PA对PA-介导的蛋白合成的抑制与相应的同源七聚体混合物的抑制作用进行的比较。野生型PA63同源七聚体和K397D+D425K,ΔD2L2,F427A,K397D,及D425K突变体如上所述进行制备。推定的异源七聚体通过,在经胰蛋白酶处理和柱层析之前,将每种PA与野生型PA以1∶1的比例混合而制备的(图11)。野生型PA(1nM),异源七聚体(H)(终浓度2nM),或相应的突变体的同源七聚体和野生型的七聚体的等摩尔混合物(M)(每种1nM)与CHO-K1细胞一起,在LFnDTA(100pM)存在下培养18小时,如上述测定其对蛋白合成的抑制,参见图9。七聚体的浓度按单体PA63亚单元表示。蛋白合成用占不添加PA的对照百分比来表示。报道了三次实验SEM的平均值。培养4小时后所观察到的结果类似。
前孔和抗-SDS寡聚体的形成
前孔和抗-SDS寡聚体的形成是通过将等摩尔量的LFn与nPA在室温下一起培养30分钟。为确定是否已形成了前孔,将所述样品用4-12%自然梯度凝胶(FMC),以50mM CHES,pH 9.0,2mg/ml CHAPS作为电泳缓冲液进行电泳。为确定是否低pH诱导抗-SDS的七聚体形成,向溶液中添加100mM醋酸钠,pH4.5至所述溶液的pH达5.0然后将所述样品于室温下温育30分钟。然后将样品溶于SDS-PAGE样品缓冲液中在4-12% SDS-PAGE梯度凝胶中电泳。样品中的蛋白可经考马斯亮蓝染色观察。
铷的释放
CHO-K1细胞以2×105细胞/孔的密度接种于培养板在37℃下培养24小时。吸出上述培养基换为含有1μCi/ml 86RbCl的培养基培养16小时。将所述细胞在冰上冷却20分钟,去除培养基。洗细胞,然后加入于HEPES缓冲培养基中的nPA(2×10-8M)。将所述的细胞与nPA在冰上处理2小时,然后加入pH5.0的缓冲液。30分钟后,收集上清液中的样品,用闪烁计数器记数以确定所释放的86Rb的量。
这一标准试验还用于确定其它孔形成毒素有关86Rb的释放量的效果。因此,本发明的其它突变体毒素也可以用这一试验进行测定其是否具有减弱的孔形成能力。
实施例2:大多数突变体形成抗-SDS寡聚体失败
所有列于表1的PA突变体#1-12和野生型PA蛋白均依照上述经胰蛋白酶水解缺刻,形成的缺口PA(nPA)蛋白在SDS-PAGE分析中作为低分子量样品迁移(图2A)。由列于表1的突变体#1-12形成可被SDS解离的前孔可以通过与单体nPA相比,与LFn复合的PA63七聚体在天然凝胶中的迁移率的降低来检测(图2B)。由K397A和D425A PA突变体形成的前孔进一步得到下述结果的支持,由MonoQ柱洗脱上述前孔比洗脱单体PA所用的盐浓度高。还对nPA突变体形成抗-SDS寡聚体进行了分析。用LFn处理野生型PA作为阳性对照。低pH脉冲将野生型PA转化成抗-SDS寡聚体,当进行SDS-PAGE分析时,其作为高分子量复合物迁移。ΔD2L2(缺少第302-325位残基的PA)和K397Q(图2B)。当用低pH处理野生型,K397Q,F427A,和ΔD2L2 PA形成的抗-SDS寡聚体(图2A和表1)。
实施例3:突变体在膜上形成孔的失败
大多数的PA突变体形成抗-SDS寡聚体失败表明在细胞膜上形成孔受到抑制。如实施例1中所述,将nPA蛋白与载有放射活性的钾类似物86Rb的细胞相结合,经低pH脉冲处理,再检测释放到培养基周围的86Rb来检测孔的形成。野生型的nPA诱导86Rb释放是由于nPA插入到膜上形成离子能通过的孔。相反,列于表1中的任何突变体#1-12均不诱导86Rb的释放(图3和表1)。因此,使大多数PA突变体失去形成抗-SDS寡聚体(实施例2)的能力与这些突变体失去在膜上形成孔的能力相关。
实施例4:PA突变体跨膜转运LFn失败
孔的形成对依赖PA的配体(即,LF,EF或LFn)转运而言是必须的步骤。用细胞表面转运试验直接测定PA配体向细胞质中的转运(实施例1)。任何列于表1中的PA突变体#1-12均没有显著下降的结合LFn的能力(图4A);但在这一试验中所有被分析的突变体转运LFn的能力均明显下降(图4B和12)。SSSR对照突变体在此条件下几乎不引起抑制。这些数据表明突变体保持了结构完整性及与细胞受体和LFn结合的能力,但不能形成孔或跨膜转运配体。
实施例5:PA突变体跨膜转运LFnDTA失败
用于测定PA配体跨膜转运的另一种方法是LFnDTA毒性试验(实施例1)。在这一试验中,用PA和含有与白喉毒素DTA A-链(LFnDTA)融合的LFn的配体处理CHO细胞。经转运的白喉毒素A-链ADP核糖基化细胞质蛋白EF-2,使蛋白合成受到抑制并诱导细胞死亡。如实施例4中所测定的,这一试验是由与细胞表面相对的内体区室转运配体的估算尺度。与LFnDTA和野生型或突变体PA一起培养后,洗细胞,然后在添加了3H-亮氨酸但无亮氨酸的培养基中培养。如果蛋白合成没有受到抑制,3H-亮氨酸将掺入到新合成的蛋白中。如果蛋白合成受到LFnDTA抑制,就几乎没有3H掺入。所有的受试突变体在这一试验中均未明显抑制蛋白合成(图5)。这一结果进一步支持了下述的假设,即由于PA突变体明显缺乏孔形成,则导致这些突变体PA配体膜转运能力下降。
实施例6:PA突变体抑制野生型PA孔形成
由于所有列于表1的PA突变体#1-12都在孔形成方面存在缺陷,则测试这些突变体以确定它们是否可与野生型的PA形成失活的异源-寡聚体,从而抑制PA-介导的配体跨膜转运。ΔD2L2,K397D+D425K,和K395D+K397D+D425K+D426K PA以这种方式抑制野生型PA。当与等摩尔的野生型PA混合时,在细胞表面转运试验中,这三种突变体中的每一种均显著地抑制35S-LFn向细胞内的转运(图6)。35S-LFn与细胞的结合并未受到抑制(图6)。
实施例7:PA突变体对野生型PA孔形成的抑制
也测定了这三种突变体蛋白对PA介导的LFnDTA毒性的作用。在LFnDTA试验中,当ΔD2L2,K397D+D425K双突变体,或K395D+K397D+D425K+D426K四重突变体PA与等摩尔量的野生型PA混合时,野生型PA-介导的3H-Leu抑制存在约2-log下降(图7)。因此,所述的突变体抑制99%PA-介导的转运。存在突变体蛋白而仍有活性保留的情况可能是由于含7个野生型PA分子而没有突变体PA分子(WT7Mut0)的缘故。利用Pascal三角,预计等摩尔混合的野生型和突变体PA的七聚体的1%是100%野生型(WT7Mut0)(表2)。这一计算结果与经试验测得的在所述混合物中残余1%的活性是一致的。在LFnDTA试验中,用不同比例的野生型与ΔD2L2或K397D+D425K突变体PA所做的抑制研究表明在所述混合物中的唯一活性组分可能是WT7Mut0。包含1分子ΔD2L2或K397D+D425K PA的多数七聚体是非活性的(表2),这进一步支持了这些抑制剂的显性负本质。表2.由多种比例的突变体与野生型PA形成的预计的和测定的PA寡聚体组合物
预计的全部七聚体的百分比 保持有活性的部分
突变体:WT(mole:mole) | WT7Mut0 | WT6Mut1 | WT5Mut2 | ΔD2L2混合物 | K397D+D425A Mi |
1∶1 | 0.78% | 6% | 22% | 0.7%±.2 | 0.9%+.06 |
0.75∶1 | 2 | 10.4 | 23.5% | 3.8%±2 | 1.2%±.2 |
0.5∶1 | 5.8 | 25.8 | 56.8 | 13.5%±.5 | 5.8%+3.6 |
0.25∶1 | 21 | 57 | 85 | 14.3%±2 | 10%±2 |
预计值表示总的七聚体的百分比,预计其至少具有所示的含有多种比例的突变体与野生型PA混合物中野生型分子的数量。WT7Mut0栏表示预计包含7个野生型PA分子的总七聚体的百分率。WT6Mut1栏表示预计包含至少6个野生型PA分子的七聚体的百分率(即,所述的七聚体或包含6个野生型的PA分子和1个突变体PA分子或包含7个野生型PA分子和0个突变体PA分子。类似的WT5Mut2栏表示预计包含至少5个野生型PA分子的总七聚体的百分率。这些值是用Pascal三角计算出的。列于“保留活性”的值是在这些混合物中通过试验观察到的值。
在LFnDTA试验中用野生型PA滴定突变体进一步描述了野生型PA抑制作用的特性。将其中的一种突变体以递增的量添加到带有野生型PA和LFnDTA的细胞培养物中(图8A)。所述的具有由164RKKR167到164SSSR167突变的弗林蛋白酶识别位点的突变体PA-SSSR包含于其中作为对照。所述的突变体不能被弗林蛋白酶或其它弗林蛋白酶-样蛋白酶形成缺刻,因此不能形成孔。该突变体仅通过与受体的竞争抑制PA。ΔD2L2和K397D+D425K在很大程度上抑制PA介导的转运。重要的是因为与PA-SSSR所需要的蛋白相比,这些突变体只需要极少的蛋白即可观察到50%的抑制,所以这些突变体并不是通过竞争受体而单独地抑制(图7B)。单一突变体包括K397D+D425K中的单一突变体组分与双突变体抑制程度不同,但比PA-SSSR抑制作用强。综合考虑这些数据表明ΔD2L2,K397D+D425K,和K395D+K397D+D425K+D426K PA是野生型PA的显性负抑制剂。
所述的F427A,D425K,K397D+D425K+F427A,F427A+ΔD2L2,K397D+F427A+ΔD2L2 PA突变体显性负抑制剂也进行了测定。在这一试验中,如上所述,递增数量的PA突变体形式与衡量的野生型PA相混合。这一组中最有效的成员K397D+D425K+F427A三重突变体在毒素1∶1比率的突变体:野生型PA的情况下几乎完全阻止了毒素的活性。D2L2,K397D+D425K,F427A,F427A+ΔD2L2,和K397D+F427A+ΔD2L2 PA突变体也有抑制剂活性。K397D+D425K+F427A+ΔD2L2,F427D,和F427K PA突变体在LFnDTA毒性试验中也表现出显性负活性。相反,另一种转运缺失突变体K397D在1∶1的比率下事实上没有表现抑制,由此说明并非所有的这种类型的突变体均是强抑制剂(图9)。所述的S SSR对照突变体即使在超过野生型PA10倍的情况下也不引起可检测到的毒素抑制作用,暗示与受体的竞争作用不对其它突变体的抑制剂活性起主要作用。
用经纯化的同源-和异源七聚体验证了显性负突变体的抑制作用依赖其PA63组分与野生型PA63形成杂种复合体的能力的假说。溶液中的PA可通过适度的胰蛋白酶作用在弗林蛋白酶位点切割,所得的片段在离子交换柱上通过胰蛋白酶-缺刻分子层析分离(Miller等,Biochemistry38,10432,1999)。经此种方法分离的纯化的PA63是七聚体,这表明低聚反应平衡在很大程度上有利于此种形式,且可能与前孔在结构上相似或同一。纯化的同源七聚体是由野生型PA和K397D+D425K,ΔD2L2,F427A,D425K,和K397D转运缺陷PA突变体中的一种制备的。推定的异源七聚体是通过下述方式制备的:将每种突变体PA与野生型PA以1∶1的比例混合,接下来使所述混合物胰蛋白酶化并在离子交换柱上将所述产物进行层析。
通过每一种异源七聚体和1∶1混合的相应突变体和野生型同源七聚体测定了LFnDTA依赖的蛋白合成的抑制。含K397D+D425K,ΔD2L2,F427A和D425K突变体的异源七聚体不介导LFnDTA的作用,而相应的同源七聚体混合物具有高度的活性(图11)。与此相反,通过混合K397D和野生型PA形成的确定异源七聚体与由同源-K397D PA和同源-野生型PA混合形成的混合物一样具有活性。这些结果与图9中所示试验中这些突变体的性质一致,并支持下述概念,即显性负突变体的PA63通过与之共寡聚化灭活野生型蛋白。在异源七聚体制剂中K397D缺乏抑制剂活性反映出其与野生型蛋白共-寡聚化的能力的缺陷或在七聚体中抑制其活性的能力的缺陷。突变体同源七聚体不抑制野生型的活性的发现表明,在所述试验条件下几乎不存在受体的竞争并且在七聚体之间几乎没有或没有亚单位的交换。
如上所述,在这些LFnDTA毒性试验中K397D+D425K双突变体几乎完全封阻的活性表明所述突变体的单个分子灭活七聚体且寡聚体化是随机的。ΔD2L2,D425K,和F427A突变体表现为稍弱的抑制性,暗示每七聚体这些突变体中不只一个分子对于灭活和/或它们与野生型PA的共寡聚体化不是纯粹随机的。其它的因素,例如向正生长的七聚体复合物中添加B组分(例如,最先或最后添加的B组分)的顺序也影响灭活作用。本说明书中所述的任何建议的有关抑制的机制均不应视为对本发明的限制。
实施例8:含突变体和野生型PA的抗-SDS寡聚体的形成
为检测ΔD2L2和K397D+D425K突变体与野生型PA的相互作用,将等摩尔比例的突变体及野生型PA相混合,用胰蛋白酶断裂形成缺刻,并通过SDS-PAGE分析抗-SDS寡聚体的形成。每当一种突变体与野生型PA即形成一种新的抗-SDS PA。与单独的野生型PA在凝胶中产生分散的高分子量成片条带不同,突变体和野生型PA的混合物形成明显的高分子量条带。这一明显条带与所观察到的单独的突变体所形成的条带也有区别:单独的K397D+D425K不形成抗-SDS寡聚体,单独的ΔD2L2 PA所形成的寡聚体在凝胶中比同时存在野生型PA时形成的条带迁移得更远。尽管确切的组合物以及这一条带的性质尚未确定了,但这一条带进一步暗示在抗-SDS寡聚体中突变体与野生型PA的相互作用导致寡聚体在凝胶中迁移率的改变。
实施例9:体内毒素抑制
在体外显性负突变体表现出的性质暗示它们应当在体内抑制毒素作用。为验证这一假说在用于炭疽毒素的传统体内模型Fisher 344 rat(Ivins等,Appl.Environ.Microbiol.55:2098,1989)中检测了这三种突变体(K397D+D425K,ΔD2L2,和F427A)的活性。静脉注射了8μg LF和40μg PA混合物(约为最低致死剂量的10倍)的雄鼠(250-300g)在约90分钟表现垂死状态(表3)。用任意的显性负突变体替换野生型PA时,在所述动物被处死前两周的时间内未表现出中毒症状。当注射前将显性负PA添加到野生型PA/LF混合物中时,无论以相对于野生型PA1∶1的比例(40μg显性负PA)还是0.25∶1的比例(10μg显性负PA)注射的动物均无症状地存活下来。所述的SSSR突变体对所述毒素的活性几乎不起作用。这些结果与体外试验的结果一致,表明显性负突变体甚至在相对于野生型PA的亚化学剂量(0.25∶1)下也可以在体内切除炭疽毒素的作用。
表3:在体内PA突变体对野生型PA的抑制
蛋白总量(μg)
WT ΔD2L2 K397D+D425K F427A SSR TTM
40 - - - - 90±11分钟
- 40 - - - 存活
- - 40 - - 存活
- - - 40 - 存活
40 40 - - - 存活
40 - 40 - - 存活
40 - - 40 - 存活
40 - - - 40 100±3分钟
40 10 - - - 存活
40 10 - - 存活
40 - - 10 - 存活
比较了K397D+D425K双突变体(″二联体″)和K397D+D425K+F427A三重突变体(″三联体″)在体内抑制野生型PA活性的能力(表4)。如上所述用40μg野生型PA,10μg LF以及PBS或显性负PA突变体的混合物注射大鼠进行这一试验。
表4:在体内PA突变体对野生型PA的抑制
动物 突变体PA的量 TTMPBS 2 - ~100分钟两倍 2 40μg 存活三倍 2 40μg 存活两倍 4 4μg 存活三倍 4 4μg 存活
还用K397D+D425K,ΔD2L2,或F427A PA测定了对大鼠接种疫苗所产生的抗-PA和中和抗体滴度。为进行这一鉴定,以6只动物为一组的多组动物分别在第0,3,6周接受了三次进入后四分之一内的肌内注射疫苗接种,所注射的是于200μl Ribi Tri-Mix佐剂(Sigma)中的50μg蛋白。在第一次注射的两天前和每次注射后的14天从每只动物抽血收集血清。最后一次注射后16天用致死剂量LF(30μg PA+6μg LF)如表5所述进行第IV次注射。用抗PA标准ELISA试验确定血清中的平均抗-PA抗体滴度。报告的是使血清反应性终止的滴度的几何平均数的倒数。在LFnDTA试验中,以1×10-10M PA和1×10-10M LFnDTA滴定中和抗体。在开始试验前,将抗体稀释物与PA一起于37℃下培养1小时。如上所述用LFnDTA毒性试验测定蛋白合成抑制。所述的中和滴度代表抑制PA活性50%所需稀释度的几何平均数的倒数。如表5中所述,在Fisher大鼠中K397D+D425K,ΔD2L2,和F427A PA突变体相对于野生型PA几乎没有或没有表现出免疫原性减弱。无论所用的免疫原如何,进行三次注射后的中和和抗-PA抗体滴度相似,且经疫苗接种的动物在最后一次注射后的16天抵抗住所施用的致死剂量的野生型PA加LF,存活下来。表5:由PA突变体对大鼠进行疫苗接种所产生的抗-PA和中和抗体滴度
动物 抗-PA滴度 中和滴度 TTMPBS 6 <10 <10 74.2±1.5WT 5 43,300 2,490 存活ΔD2L2 6 47,500 3,350 存活K397D+ 6 65,500 2,260 存活D425KF427A 6 132,000 6,090 存活
实施例10:针对PA的抗体
针对PA的抗体可以用于治疗和/或诊断。可以标准的方法通过PA蛋白或其片段免疫攻击含B细胞的生物系统,例如某种动物如小鼠或兔,以刺激B细胞产生抗-PA抗体,接下来从所述生物系统中分离产生的抗体。为产生单克隆抗体,从具有对PA蛋白最高的ELISA确定的免疫应答的动物中收获脾,将所述的B细胞与NS-1骨髓瘤细胞融合以产生杂交瘤。用标准的ELISA试验或Western印迹筛选分泌可与PA结合的抗体的杂交瘤。保留产生高抗体滴度并特异识别PA蛋白的单克隆细胞系。
也可以筛选出所述的细胞系用于鉴别产生对突变体PA蛋白比对天然存在的PA具有更高亲和力的抗体的细胞系。这些抗体可以通过对动物施用包含如K397,D425,D426,或F427残基的天然存在的PA片段而产生。筛选所得的抗体以确定那些可与天然存在的PA结合但不与K397,D425,D426,或F427中的一个或多个残基突变或缺失的突变体PA蛋白结合。例如,可将所得的抗体可通过含有固定了突变体PA蛋白的柱,则可以筛选出不与突变体PA蛋白结合的抗体。也可以生产出可与D2L2环上的残基反应的;这些抗体可以如上所述通过向动物施用含D2L2环的PA片段产生。可与天然存在的PA中的D2L2环上的残基反应的抗体也可以通过筛选不与D2L2环上一个或多个残基缺失的突变体PA蛋白结合的抗体而产生。另外,也可以产生与对突变体PA比对天然存在的PA分子具有更强亲和力的抗体,这样的抗体可以如上所述通过向动物施用突变体PA并筛选对突变体PA形式具有更强亲和力的抗体。这些抗体可与不存在于天然PA中而存在与突变体PA中的残基结合。
抗-PA抗体可以用于检测生物样品,如血清中的PA蛋白,所述的检测是将所述的样品与所述抗体接触,然后测定免疫复合物作为测定样品中的PA蛋白的尺度。因此,这些抗体可以用作确定受试者是否已暴露于炭疽毒素的试剂盒。
针对PA的抗体也可以用作治疗或预防炭疽感染的治疗剂。如果可与野生型PA结合但不与显性负PA突变体结合的抗-PA抗体施用于受试者作为抗炭疽感染被动免疫,显性负PA突变体也可以施用于同一受试者作为抑制野生型PA活性的治疗剂。由于所施用的抗-PA抗体不与治疗性的显性负PA突变体反应,抗-PA抗体不应减弱显性负PA突变体抑制野生型PA的能力。另外,不与治疗剂反应的抗-PA抗体可用于确定存在于从用显性负PA突变体治疗的受试者获得的样品中的野生型PA的量。
也可以产生针对本发明的其它突变体B组分的类似抗体。
实施例11:PA蛋白和片段的施用
施用本发明的片段或蛋白并不局限于特定的施用方式,剂量,或剂量频率;目前的方式包括所有的施用方式,即包括口,肌肉内,静脉内,皮下,经吸入,或其它足以提供充分预防或治疗炭疽感染的剂量。一种或多种突变体PA蛋白或片段可以在单剂量或多剂量中施用于哺乳动物。当多剂施用时,每剂之间可以间隔,例如一周到一个月。应当理解,对于任何特定的受试者应当根据个体的需要施用以及或监督所述组合物施用的人员的职业判断,在整个过程中调整剂量方案。
可以根据E.W.Martin在Remingtion′s PharmaceuticalSciences的描述制备包含一种或多种本发明的PA蛋白或片段的药物组合物。可以使用药物稳定化合物,递送载体,运输载体或佐剂。例如,也可以用人血清白蛋白或其它人或动物蛋白。磷脂载体或脂质体悬液是可能的药用载体或递送载体。可用于本发明中的佐剂包括:铝化合物,如氢氧化铝,磷酸铝和羟基磷酸铝。这些组合物可用本领域技术人员已知的方法制备。
本发明的其它B组分或片段也可以类似地施用。
实施例12:其它孔形成突变体
PA的晶体结构确定了四个PA结构域(Petosa等,Nature385(6619):833-838,1997)。结构域2(第259-487位残基)包含大的可变形的环,其在由前孔到孔的转换过程中经历主要的构象改变。在这一区域突变,缺失或插入一个或多个氨基酸在体内可导致该蛋白的孔形成能力受到抑制和/或导致PA突变体抑制天然存在的PA的孔形成能力。例如,与其它一个或多个孔形成毒素(如来自艰难梭菌(Clostridium difficile),产气荚膜梭菌(C.perfringens),螺状梭菌(C.spiroforme),肉毒梭菌(C.botulinum),蜡状芽孢杆菌(Bacillus cereus),或苏云金芽孢杆菌(B.Thuringiensis)的毒素;图15和16)中的相应的残基相同的PA结构域2中的残基也可能发生突变。这些残基可能在PA中突变或缺失以形成显性负PA突变体。
下述PA结构域2中的残基在列于图15和16中由两个组分组成的A-B毒素中是不变的:A259,P260,V262,V264,M266,E267,S272E275 T298,N353,N361,N363 R365,Y366,N368,G370,T371,Y375,V377,P389,T380,T381,V384,T393,I394,P407,Y411,P412,A420,D425,F427,I432,N435,Q438,L450,T452,Q454,G457,G474,W477,和I484。这些残基可以突变成其它任何氨基酸。例如,这些残基可以变为带有小的侧链的氨基酸,如甘氨酸和丙氨酸,所述的氨基酸也可以变为带有大的或支链侧链的氨基酸,如色氨酸,亮氨酸和甲硫氨酸。其它可用于替换天然存在的残基的残基的实施例列于表1。
除炭疽毒素外,本发明还涉及其它孔形成毒素。这些毒素也可以突变以产生减弱的或可忽略的寡聚化,形成跨膜通道或转运配体能力的毒素。另外也可以产生其它孔形成突变体的显性负突变体。相应于此处所述的PA突变体的突变体也可以由其它与PA同源的毒素制备(如来自艰难梭菌(Clostriidum difficile),产气荚膜梭菌(C.perfringens),螺状梭菌(C.spiroforme),肉毒梭菌(C.botulinum),蜡状芽孢杆菌(Bacillus cereus),或苏云金芽孢杆菌(B.Thuringiensis)的毒素)(图15和16和表6)。相应于PA结构域2中的残基的其它毒素中的残基也可以如上所述进行突变。另外,在其它孔形成毒素中至少相应于PA的D2L2环区域的1,3,5,8,10,15,20,或24个氨基酸可以缺失。在相应于此处所述的突变PA残基的残基处可进行一个或多个点突变。
可将任何一种孔形成毒素的突变体施用于哺乳动物以治疗和预防产生相应毒素的病原体(如,细菌)感染。
表6.相应于此处所述的炭疽PA中突变的其它孔形成毒素中的突变。在其它孔形成毒素中相应于PA中突变的残基的残基也可以突变为任何其它氨基酸。
炭疽PA | 艰难梭菌(C.difficile)毒素 | 产气荚膜梭菌(C.perfringens)毒素 | 螺状梭菌(C.spiroforme)毒素 | 肉毒梭菌(C.botulinum)毒素 | 蜡状芽孢杆菌(B.Cereus)毒素 |
K397A | Q425A | Q424A | Q428A | Q398A | K879A |
K397D | Q425D | Q424D | Q428D | Q398D | K879D |
K397C | Q425C | Q424C | Q428C | Q398C | K879C |
K397Q | Q425Q | Q424Q | Q428Q | Q398Q | K879Q |
D425A | D453A | D452A | D456A | D426A | D907A |
D425N | D453N | D452N | D456N | D426N | D907N |
D425E | D453E | D452E | D456E | D426E | D907E |
D425K | D453K | D452K | D456K | D426K | D907K |
F427A | F455A | F454A | F458A | F428A | F909A |
K397D+D425K | Q425D+D453K | Q424D+D452K | Q428D+D456K | Q398D+D426K | K879D+D907K |
K395D+K397D+D425K+D426K | K423D+Q425D+D453K+Q454K | K422D+Q424D+D452K+Q453K | K426D+Q428D+D456K+Q457K | K396D+Q398D+D426K+Q427K | T877DK879D+D907K+D908K |
ΔD2L2 | Δ340-358 | Δ339-357 | Δ343-361 | Δ307-331 | Δ797-816 |
K397D+D425K+F427A | Q425D+D453K+F455A | Q424D+D452KF454A+ | Q428D+D456K+F458A | Q398D+D426K+F428A | K879D+D907K+F909A |
F427A+ΔD2L2 | F455A+Δ340-358 | F454A+Δ339-357 | F458A+Δ343-361 | F428A+Δ307-331 | F909A+Δ797-816 |
K397D+F427A+ΔD2L2 | Q425D+F455A+Δ340-358 | Q424D+F454A+Δ339-357 | Q428D+F458A+Δ343-361 | Q398D+F428A+Δ307-331 | K879D+F909A+Δ797-816 |
K397D+D425K+F427A+ΔD2L2 | Q425D+D453K+F455A+Δ340-358 | Q424D+D452K+F454A+Δ339-357 | Q428D+D456K+F458A+Δ343-361 | Q398D+D426K+F428A+Δ307-331 | K879D+D907K+F909A+Δ797-816 |
F427D | F455D | F454D | F458D | F428D | F909D |
F427K | F455K | F454K | F458K | F428K | F909K |
另外,可以用标准的分子生物学方法对编码孔形成突变体(如依赖胆固醇的溶细胞素或与葡萄球菌α-毒素相关的六聚体或七聚体的毒素)的核酸进行随机诱变。编码的突变体毒素可以用标准的方法表达或选择性纯化。此处所述的铷释放试验可用于鉴定具有减弱的形成跨膜通道能力的突变体毒素。另外动物模型可以用于鉴定显性负毒素突变体,当所述的突变体和野生型毒素均施用于动物时,所述的突变体减弱相应的野生型毒素的毒性。
其它实施例
在本说明书中所提及的所有出版物和专利申请均以相同的程度引入本申请,此处,如同每篇单独的出版物或专利申请均特别地、单独地列出以并入本文。
虽然本发明通过特定的实施例进行描述,应当理解本发明可以被进一步修改,而本申请试图涵盖一般根据本发明的原理所作的任何变更、应用或修改,并包括下述的本发明的背离,所谓背离是指在本发明所从属于的领域中所公知或常用的,适用于在上文中所述的本发明基本特征的,并遵循以下所附的权利要求书中所述的范围的范围内。
其它的实施方案包含在权利要求书中。
序列表<110>哈佛大学校长及研究员协会<120>治疗和预防细菌感染的化合物和方法<130>00742/060CN2<150>PCT/US01/14372<151>2001-05-04<150>US 60/201,800<151>2000-05-04<160>35<170>FastSEQ,Windows版本4.0<210>1<211>736<212>PRT<213>炭疽杆菌<400>1Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>2<211>736<212>PRT<213>炭疽杆菌<400>2Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala G1u Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>3<211>736<212>PRT<213>炭疽杆菌<400>3Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>4<211>736<212>PRT<213>炭疽杆菌<400>4Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His ValThr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>5<211>736<212>PRT<213>炭疽杆菌<400>5Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val ValLys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>6<211>736<212>PRT<213>炭疽杆菌<400>6Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val ValThr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720lle Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>7<211>736<212>PRT<213>炭疽杆菌<400>7Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>8<211>736<212>PRT<213>炭疽杆菌<400>8Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>9<211>736<212>PRT<213>炭疽杆菌<400>9Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>10<211>736<212>PRT<213>炭疽杆菌<400>10Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>11<211>736<212>PRT<213>炭疽杆菌<400>11Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser 1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>12<211>736<212>PRT<213>炭疽杆菌<400>12Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>13<211>736<212>PRT<213>炭疽杆菌<400>13Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>14<211>736<212>PRT<213>炭疽杆菌<400>14Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>15<211>736<212>PRT<213>炭疽杆菌<400>15Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn ValSer Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>16<211>736<212>PRT<213>炭疽杆菌<400>16Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val Hi
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val ValLys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>17<211>736<212>PRT<213>炭疽杆菌<400>17Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>18<211>736<212>PRT<213>炭疽杆菌<400>18Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>19<211>736<212>PRT<213>炭疽杆菌<400>19Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val
470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>20<211>736<212>PRT<213>炭疽杆菌<400> 20Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>21<211>736<212>PRT<213>炭疽杆菌<400>21Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr ValAla Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>22<211>2208<212>DNA<213>炭疽杆菌<400>22gaagttaaac aggagaaccg gttattaaat gaatcagaat caagttccca ggggttacta 60ggatactatt ttagtgattt gaattttcaa gcacccatgg tggttacctc ttctactaca 120ggggatttat ctattcctag ttctgagtta gaaaatattc catcggaaaa ccaatatttt 180caatctgcta tttggtcagg atttatcaaa gttaagaaga gtgatgaata tacatttgct 240acttccgctg ataatcatgt aacaatgtgg gtagatgacc aagaagtgat taataaagct 300tctaattcta acaaaatcag attagaaaaa ggaagattat atcaaataaa aattcaatat 360caacgagaaa atcctactga aaaaggattg gatttcaagt tgtactggac cgattctcaa 420aataaaaaag aagtgatttc tagtgataac ttacaattgc cagaattaaa acaaaaatct 480tcgaactcaa gaaaaaagcg aagtacaagt gctggaccta cggttccaga ccgtgacaat 540gatggaatcc ctgattcatt agaggtagaa ggatatacgg ttgatgtcaa aaataaaaga 600acttttcttt caccatggat ttctaatatt catgaaaaga aaggattaac caaatataaa 660tcatctcctg aaaaatggag cacggcttct gatccgtaca gtgatttcga aaaggttaca 720ggacggattg ataagaatgt atcaccagag gcaagacacc cccttgtggc agcttatccg 780attgtacatg tagatatgga gaatattatt ctctcaaaaa atgaggatca atccacacag 840aatactgata gtgaaacgag aacaataagt aaaaatactt ctacaagtag gacacatact 900agtgaagtac atggaaatgc agaagtgcat gcgtcgttct ttgatattgg tgggagtgta 960tctgcaggat ttagtaattc gaattcaagt acggtcgcaa ttgatcattc actatctcta 1020gcaggggaaa gaacttgggc tgaaacaatg ggtttaaata ccgctgatac agcaagatta 1080aatgccaata ttagatatgt aaatactggg acggctccaa tctacaacgt gttaccaacg 1140acttcgttag tgttaggaaa aaatcaaaca ctcgcgacaa ttaaagctaa ggaaaaccaa 1200ttaagtcaaa tacttgcacc taataattat tatccttcta aaaacttggc gccaatcgca 1260ttaaatgcac aagacgattt cagttctact ccaattacaa tgaattacaa tcaatttctt 1320gagttagaaa aaacgaaaca attaagatta gatacggatc aagtatatgg gaatatagca 1380acatacaatt ttgaaaatgg aagagtgagg gtggatacag gctcgaactg gagtgaagtg 1440ttaccgcaaa ttcaagaaac aactgcacgt atcattttta atggaaaaga tttaaatctg 1500gtagaaaggc ggatagcggc ggttaatcct agtgatccat tagaaacgac taaaccggat 1560atgacattaa aagaagccct taaaatagca tttggattta acgaaccgaa tggaaactta 1620caatatcaag ggaaagacat aaccgaattt gattttaatt tcgatcaaca aacatctcaa 1680aatatcaaga atcagttagc ggaattaaac gcaactaaca tatatactgt attagataaa 1740atcaaattaa atgcaaaaat gaatatttta ataagagata aacgttttca ttatgataga 1800aataacatag cagttggggc ggatgagtca gtagttaagg aggctcatag agaagtaatt 1860aattcgtcaa cagagggatt attgttaaat attgataagg atataagaaa aatattatca 1920ggttatattg tagaaattga agatactgaa gggcttaaag aagttataaa tgacagatat 1980gatatgttga atatttctag tttacggcaa gatggaaaaa catttataga ttttaaaaaa 2040tataatgata aattaccgtt atatataagt aatcccaatt ataaggtaaa tgtatatgct 2100gttactaaag aaaacactat tattaatcct agtgagaatg gggatactag taccaacggg 2160atcaagaaaa ttttaatctt ttctaaaaaa ggctatgaga taggataa 2208<210>23<211>736<212>PRT<213>炭疽杆菌<400>23Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His ValThr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Glx
725 730 735<210>24<211>599<212>PRT<213>炭疽杆菌<400>24Thr Asp Ser Gln Asn Lys Lys Glu Val Ile Ser Ser Asp Asn Leu Gln1 5 10 15Leu Pro Glu Leu Lys Gln Lys Ser Ser Asn Ser Arg Lys Lys Arg Ser
20 25 30Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile Pro
35 40 45Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys Arg
50 55 60Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly Leu65 70 75 80Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp Pro
85 90 95Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val Ser
100 105 110Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr Pro Ile Val His Val
115 120 125Asp Met Glu Asn Ile Ile Leu Ser Lys Asn Glu Asp Gln Ser Thr Gln
130 135 140Asn Thr Asp Ser Gln Thr Arg Thr Ile Ser Lys Asn Thr Ser Thr Ser145 150 155 160Arg Thr His Thr Ser Glu Val His Gly Asn Ala Glu Val His Ala Ser
165 170 175Phe Phe Asp Ile Gly Gly Ser Val Ser Ala Gly Phe Ser Asn Ser Asn
180 185 190Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser Leu Ala Gly Glu Arg
195 200 205Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala Asp Thr Ala Arg Leu
210 215 220Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr Ala Pro Ile Tyr Asn225 230 235 240Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys Asn Gln Thr Leu Ala
245 250 255Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser Gln Ile Leu Ala Pro Asn
260 265 270Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile Ala Leu Asn Ala Gln
275 280 285Asp Asp Phe Ser Ser Thr Pro Ile Thr Met Asn Tyr Asn Gln Phe Leu
290 295 300Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp Thr Asp Gln Val Tyr305 310 315 320Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly Arg Val Arg Val Asp
325 330 335Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln Ile Gln Glu Thr Thr
340 345 350Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn Leu Val Glu Arg Arg
355 360 365Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu Thr Thr Lys Pro Asp
370 375 380Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe Gly Phe Asn Glu Pro385 390 395 400Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile Thr Glu Phe Asp Phe
405 410 415Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys Asn Gln Leu Ala Glu
420 425 430Leu Asn Val Thr Asn Ile Tyr Thr Val Leu Asp Lys Ile Lys Leu Asn
435 440 445Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg Phe His Tyr Asp Arg
450 455 460Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala His465 470 475 480Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile Asp
485 490 495Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu Asp
500 505 510Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu Asn
515 520 525Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys
530 535 540Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val545 550 555 560Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu
565 570 575Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser
580 585 590Lys Lys Gly Tyr Glu Ile Gly
595<210>25<211>705<212>PRT<213>艰难梭菌<400>25Glu Leu Asp Gly Met Lys Lys Ile Ile Pro Glu Glu Asn Leu Phe Leu1 5 10 15Arg Asp Tyr Ser Asn Ile Glu Lys Asp Asp Pro Phe Ile Pro Asn Asn
20 25 30Asn Phe Phe Asp Pro Lys Leu Met Ser Asp Trp Glu Asp Glu Asp Leu
35 40 45Asp Thr Asp Asn Asp Asn Ile Pro Asp Ser Tyr Glu Arg Asn Gly Tyr
50 55 60Thr Ile Lys Asp Leu Ile Ala ValLys Trp Glu Asp Ser Phe Ala Glu65 70 75 80Gln Gly Tyr Lys Lys Tyr Val Ser Asn Tyr Leu Glu Ser Asn Thr Ala
85 90 95Gly Asp Pro Tyr Thr Asp Tyr Glu Lys Ala Ser Gly Ser Phe Asp Lys
100 105 110Ala Ile Lys Thr Glu Ala Arg Asp Pro Leu Val Ala Ala Tyr Pro Ile
115 120 125Val Gly Val Gly Met Glu Lys Leu Ile Ile Ser Thr Asn Glu His Ala
130 135 140Ser Thr Asp Gln Gly Lys Thr Val Ser Arg Ala Thr Thr Asn Ser Lys145 150 155 160Thr Glu Ser Asn Thr Ala Gly Val Ser Val Asn Val Gly Tyr Gln Asn
165 170 175Gly Phe Thr Ala Asn Val Thr Thr Asn Tyr Ser His Thr Thr Asp Asn
180 185 190Ser Thr Ala Val Gln Asp Ser Asn Gly Glu Ser Trp Asn Thr Gly Leu
195 200 205Ser Ile Asn Lys Gly Glu Ser Ala Tyr Ile Asn Ala Asn Val Arg Tyr
210 215 220Tyr Asn Thr Gly Thr Ala Pro Met Tyr Lys Val Thr Pro Thr Thr Asn225 230 235 240Leu Val Leu Asp Gly Asp Thr Leu Ser Thr Ile Lys Ala Gln Glu Asn
245 250 255Gln Ile Gly Asn Asn Leu Ser Pro Gly Asp Thr Tyr Pro Lys Lys Gly
260 265 270Leu Ser Pro Leu Ala Leu Asn Thr Met Asp Gln Phe Ser Ser Arg Leu
275 280 285Ile Pro Ile Asn Tyr Asp Gln Leu Lys Lys Leu Asp Ala Gly Lys Gln
290 295 300Ile Lys Leu Glu Thr Thr Gln Val Ser Gly Asn Phe Gly Thr Lys Asn305 310 315 320Ser Ser Gly Gln Ile Val Thr Glu Gly Asn Ser Trp Ser Asp Tyr Ile
325 330 335Ser Gln Ile Asp Ser Ile Ser AIa Ser Ile Ile Leu Asp Thr Glu Asn
340 345 350Glu Ser Tyr Glu Arg Arg Val Thr Ala Lys Asn Leu Gln Asp Pro Glu
355 360 365Asp Lys Thr Pro Glu Leu Thr Ile Gly Glu Ala Ile Glu Lys Ala Phe
370 375 380Gly Ala Thr Lys Lys Asp Gly Leu Leu Tyr Phe Asn Asp Ile Pro Ile385 390 395 400Asp Glu Ser Cys Val Glu Leu Ile Phe Asp Asp Asn Thr Ala Asn Lys
405 410 415Ile Lys Asp Ser Leu Lys Thr Leu Ser Asp Lys Lys Ile Tyr Asn Val
420 425 430Lys Leu Glu Arg Gly Met Asn Ile Leu Ile Lys Thr Pro Thr Tyr Phe
435 440 445Thr Asn Phe Asp Asp Tyr Asn Asn Tyr Pro Ser Thr Trp Ser Asn Val
450 455 460Asn Thr Thr Asn Gln Asp Gly Leu Gln Gly Ser Ala Asn Lys Leu Asn465 470 475 480Gly Glu Thr Lys Ile Lys Ile Pro Met Ser Glu Leu Lys Pro Tyr Lys
485 490 495Arg Tyr Val Phe Ser Gly Tyr Ser Lys Asp Pro Leu Thr Ser Asn Ser
500 505 510Ile Ile Val Lys Ile Lys Ala Lys Glu Glu Lys Thr Asp Tyr Leu Val
515 520 525Pro Glu Gln Gly Tyr Thr Lys Phe Ser Tyr Glu Phe Glu Thr Thr Glu
530 535 540Lys Asp Ser Ser Asn Ile Glu Ile Thr Leu Ile Gly Ser Gly Thr Thr545 550 555 560Tyr Leu Asp Asn Leu Ser Ile Thr Glu Leu Asn Ser Thr Pro Glu Ile
565 570 575Leu Asp Glu Pro Glu Val Lys Ile Pro Thr Asp Gln Glu Ile Met Asp
580 585 590Ala His Lys Ile Tyr Phe Ala Asp Leu Asn Phe Asn Pro Ser Thr Gly
595 600 605Asn Thr Tyr Ile Asn Gly Met Tyr Phe Ala Pro Thr Gln Thr Asn Lys
610 615 620Glu Ala Leu Asp Tyr Ile Gln Lys Tyr Arg Val Glu Ala Thr Leu Gln625 630 635 640Tyr Ser Gly Phe Lys Asp Ile Gly Thr Lys Asp Lys Glu Met Arg Asn
645 650 655Tyr Leu Gly Asp Pro Asn Gln Pro Lys Thr Asn Tyr Val Asn Leu Arg
660 665 670Ser Tyr Phe Thr Gly Gly Glu Asn Ile Met Thr Tyr Lys Lys Leu Arg
675 680 685Ile Tyr Ala Ile Thr Pro Asp Asp Arg Glu Leu Leu Val Leu Ser Val
690 695 700Asp705<210>26<211>706<212>PRT<213>产气荚膜梭菌<400>26Glu Leu Asn Gly Asn Lys Thr Val Ile Pro Glu Glu Asn Leu Phe Phe1 5 10 15Arg Asp Tyr Ser Lys Ile Asp Glu Asn Asp Pro Phe Ile Pro Asn Asn
20 25 30Asn Phe Phe Asp ValArg Phe Phe Ser Ala Ala Trp Glu Asp Glu Asp
35 40 45Leu Asp Thr Asp Asn Asp Asn Ile Pro Asp Ala Tyr Glu Lys Asn Gly
50 55 60Tyr Thr Ile Lys Asp Ser Ile Ala Val Lys Trp Asn Asp Ser Phe Ala65 70 75 80Glu Gln Gly Tyr Lys Lys Tyr Val Ser Ser Tyr Leu Glu Ser Asn Thr
85 90 95Ala Gly Asp Pro Tyr Thr Asp Tyr Gln Lys Ala Ser Gly Ser Ile Asp
100 105 110Lys Ala Ile Lys Leu Glu Ala Arg Asp Pro Leu Val Ala Ala Tyr Pro
115 120 125Val Val Gly Val Gly Met Glu Asn Leu Ile Ile Ser Thr Asn Glu His
130 135 140Ala Ser Ser Asp Gln Gly Lys Thr Val Ser Arg Ala Thr Thr Asn Ser145 150 155 160Lys Thr Asp Ala Asn Thr Val Gly Val Ser Ile Ser Ala Gly Tyr Gln
165 170 175Asn Gly Phe Thr Gly Asn Ile Thr Thr Ser Tyr Sar His Thr Thr Asp
180 185 190Asn Ser Thr Ala Val Gln Asp Ser Asn Gly Glu Ser Trp Asn Thr Gly
195 200 205Leu Ser Ile Asn Lys Gly Glu Ser Ala Tyr Ile Asn Ala Asn Val Arg
210 215 220Tyr Tyr Asn Thr Gly Thr Ala Pro Met Tyr Lys Val Thr Pro Thr Thr225 230 235 240Asn Leu Val Leu Asp Gly Glu Thr Leu Ala Thr Ile Lys Ala Gln Asp
245 250 255Asn Gln Ile Gly Asn Asn Leu Ser Pro Asn Glu Thr Tyr Pro Lys Lys
260 265 270Gly Leu Ser Pro Leu Ala Leu Asn Thr Met Asp Gln Phe Asn Ala Arg
275 280 285Leu Ile Pro Ile Asn Tyr Asp Gln Leu Lys Lys Leu Asp Ser Gly Lys
290 295 300Gln Ile Lys Leu Glu Thr Thr Gln Val Ser Gly Asn Tyr Gly Thr Lys305 310 315 320Asn Ser Gln Gly Gln Ile Ile Thr Glu Gly Asn Ser Trp Ser Asn Tyr
325 330 335Ile Ser Gln Ile Asp Ser Val Ser Ala Ser Ile Ile Leu Asp Thr Gly
340 345 350Ser Gln Thr Phe Glu Arg Arg Val Ala Ala Lys Glu Gln Gly Asn Pro
355 360 365Glu Asp Lys Thr Pro Glu Ile Thr Ile Gly Glu Ala Ile Lys Lys Ala
370 375 380Phe Ser Ala Thr Lys Asn Gly Glu Leu Leu Tyr Phe Asn Gly Ile Pro385 390 395 400Ile Asp Glu Ser Cys Val Glu Leu Ile Phe Asp Asp Asn Thr Ser Glu
405 410 415Ile Ile Lys Glu Gln Leu Lys Tyr Leu Asp Asp Lys Lys Ile Tyr Asn
420 425 430ValLys Leu Glu Arg Gly Met Asn Ile Leu Ile Lys Val Pro Ser Tyr
435 440 445Phe Thr Asn Phe Asp Glu Tyr Asn Asn Phe Pro Ala Ser Trp Ser Asn
450 455 460Ile Asp Thr Lys Asn Gln Asp Gly Leu Gln Ser Val Ala Asn Lys Leu465 470 475 480Ser Gly Glu Thr Lys Ile Ile Ile Pro Met Ser Lys Leu Lys Pro Tyr
485 490 495Lys Arg Tyr Val Phe Ser Gly Tyr Ser Lys Asp Pro Ser Thr Ser Asn
500 505 510Ser Ile Thr Val Asn Ile Lys Ser Lys Glu Gln Lys Thr Asp Tyr Leu
515 520 525Val Pro Glu Lys Asp Tyr Thr Lys Phe Ser Tyr Glu Phe Glu Thr Thr
530 535 540Gly Lys Asp Ser Ser Asp Ile Glu Ile Thr Leu Thr Ser Ser Gly Val545 550 555 560Ile Phe Leu Asp Asn Leu Ser Ile Thr Glu Leu Asn Ser Thr Pro Glu
565 570 575Ile Leu Lys Glu Pro Glu Ile Lys Val Pro Ser Asp Gln Glu Ile Leu
580 585 590Asp Ala His Asn Lys Tyr Tyr Ala Asp Ile Lys Leu Asp Thr Asn Thr
595 600 605Gly Asn Thr Tyr Ile Asp Gly Ile Tyr Phe Glu Pro Thr Gln Thr Asn
610 615 620Lys Glu Ala Leu Asp Tyr Ile Gln Lys Tyr Arg Val Glu Ala Thr Leu625 630 635 640Gln Tyr Ser Gly Phe Lys Asp Ile Gly Thr Lys Asp Lys Glu Ile Arg
645 650 655Asn Tyr Leu Gly Asp Gln Asn Gln Pro Lys Thr Asn Tyr Ile Asn Phe
660 665 670Arg Ser Tyr Phe Thr Ser Gly Glu Asn Val Met Thr Tyr Lys Lys Leu
675 680 685Arg Ile Tyr Ala ValThr Pro Asp Asn Arg Glu Leu Leu Val Leu Ser
690 695 700Val Asn705<210>27<211>712<212>PRT<213>螺状梭菌<400>27Glu Leu Asn Gly Asp Lys Thr Leu Ile Pro Glu Lys Asn Leu Phe Leu1 5 10 15Arg Asp Tyr Ser Lys Ile Asp Glu Asn Asp Pro Phe Ile Pro Lys Asp
20 25 30Asn Phe Phe Asp Leu Lys Leu Lys Ser Arg Ser Ala Arg Leu Ala Ser
35 40 45Gly Trp Gly Asp Glu Asp Leu Asp Thr Asp Asn Asp Asn Ile Pro Asp
50 55 60Ala Tyr Glu Lys Asn Gly Tyr Thr Ile Lys Asp Ser Ile Ala Val Lys65 70 75 80Trp Glu Asp Ser Phe Ala Gln Gln Gly Tyr Lys Lys Tyr Leu Ser Ser
85 90 95Tyr Leu Glu Ser Asn Thr Ala Gly Asp Pro Tyr Thr Asp Tyr Gln Lys
100 105 110Ala Ser Gly Ser Phe Asp Lys Ala Ile Lys Ala Glu Ala Arg Asp Pro
115 120 125Leu Val Ala Ala Tyr Pro Val Val Gly Val Gly Met Glu Lys Leu Ile
130 135 140Ile Ser Thr Asn Glu His Ala Ser Thr Asp Gln Gly Lys Thr Val Ser145 150 155 160Arg Asn Thr Thr Asn Ser Lys Thr Asp Ala Asn Thr Ala Gly Val Ala
165 170 175Ile Asn Ile Ala Tyr Gln Asn Gly Phe Thr Gly Ser Ile Thr Thr Asn
180 185 190Tyr Ser His Thr Thr Glu Asn Ser Thr Ala Val Gln Asn Ser Asn Gly
195 200 205Glu Ser Trp Asn Thr Ser Leu Ser Ile Asn Lys Gly Glu Ser Ala Tyr
210 215 220Ile Asn Ala Asn Val Arg Tyr Tyr Asn Thr Gly Thr Ala Pro Met Tyr225 230 235 240Lys Val Thr Pro Thr Thr Asn Leu Val Leu Asp Gly Asp Thr Leu Thr
245 250 255Thr Ile Lys Ala Gln Asp Asn Gln Ile Gly Asn Asn Leu Ser Pro Asn
260 265 270Glu Thr Tyr Pro Lys Lys Gly Leu Ser Pro Leu Ala Leu Asn Thr Met
275 280 285Asp Gln Phe Ser Ser Arg Leu Ile Pro Ile Asn Tyr Asp Gln Leu Lys
290 295 300Lys Leu Asp Ala Gly Lys Gln Ile Lys Leu Glu Thr Thr Gln Val Ser305 310 315 320Gly Asn Tyr Gly Ile Lys Asn Ser Gln Gly Gln Ile Ile Thr Glu Gly
325 330 335Asn Ser Trp Ser Asp Tyr Ile Ser Gln Ile Asp Ser Leu Ser Ala Ser
340 345 350Ile Ile Leu Asp Thr Gly Ser Asp Val Phe Glu Arg Arg Val Thr Ala
355 360 365Lys Asp Ser Ser Asn Pro Glu Asp Lys Thr Pro Val Leu Thr Ile Gly
370 375 380Glu Ala Ile Glu Lys Ala Phe Gly Ala Thr Lys Asn Gly Glu Ile Leu385 390 395 400Tyr Phe Asn Gly Met Pro Ile Asp Glu Ser Cys Val Glu Leu Ile Phe
405 410 415Asp Gly Asn Thr Ala Asn Leu Ile Lys Glu Arg Leu Asn Ala Leu Asn
420 425 430Asp Lys Lys Ile Tyr Asn Val Gln Leu Glu Arg Gly Met Lys Ile Leu
435 440 445Ile Lys Thr Ser Thr Tyr Phe Asn Asn Phe Asp Gly Tyr Asn Asn Phe450 455 460Pro Ser Ser Trp Ser Asn Val Asp Ser Asn Asn Gln Asp Gly Leu Gln465 470 475 480Asn Ala Ala Asn Lys Leu Ser Gly Glu Thr Lys Ile Val Ile Pro Met
485 490 495Ser Lys Leu Asn Pro Tyr Lys Arg Tyr Val Phe Ser Gly Tyr Leu Lys
500 505 510Asn Ser Ser Thr Ser Asn Pro Ile Thr Val Asn Ile Lys Ala Lys Glu
515 520 525Gln Lys Thr Tyr Asn Leu Val Ser Glu Asn Asp Tyr Lys Lys Phe Ser
530 535 540Tyr Glu Phe Glu Thr Ile Gly Arg Asp Ala Ser Asn Ile Glu Ile Thr545 550 555 560Leu Thr Ser Ser Gly Thr Ile Phe Leu Asp Asn Leu Ser Ile Thr Glu
565 570 575Leu Asn Ser Thr Pro Glu Ile Leu Lys Glu Pro Asp Ile Lys Val Pro
580 585 590Ser Asp Gln Glu Ile Ile Asp Ala His Lys Lys Tyr Tyr Ala Asp Leu
595 600 605Ser Phe Asn Gln Ser Thr Ala Asn Tyr Tyr Leu Asp Gly Leu Tyr Phe
610 615 620Glu Pro Thr Gln Thr Asn Lys Glu Val Leu Asp Tyr Ile Gln Lys Tyr625 630 635 640Lys Val Glu Ala Thr Leu Glu Tyr Ser Gly Phe Lys Asp Ile Gly Thr
645 650 655Lys Asp Lys Glu Leu Arg Asn Tyr Thr Gly Asp Ser Asn Gln Pro Lys
660 665 670Thr Asn Tyr Val Asn Phe Arg Ser Tyr Phe Thr Ser Gly Glu Asn Val
675 680 685Met Pro Tyr Lys Lys Leu Arg Ile Tyr Ala Ile Thr Pro Glu Asn Lys
690 695 700Glu Leu Leu Val Leu Ser Ile Asn705 710<210>28<211>582<212>PRT<213>肉毒梭菌<400>28Glu Thr Ser Asp Ile Ile Lys Glu Ile Ile Pro Ser Glu Val Leu Leu1 5 10 15Lys Pro Asn Tyr Ser Asn Thr Asn Glu Lys Ser Lys Phe Ile Pro Asn
20 25 30Asn Thr Leu Phe Ser Asn Ala Lys Leu Lys Ala Asn Ala Asn Arg Asp
35 40 45Thr Asp Arg Asp Gly Ile Pro Asp Glu Trp Glu Ile Asn Gly Tyr Thr
50 55 60Val Met Asn Gln Lys Ala ValAla Trp Asp Asp Lys Phe Ala Ala Asn65 70 75 80Gly Tyr Lys Lys Tyr Val Ser Asn Pro Phe Lys Pro Cys Thr Ala Asn
85 90 95Asp Pro Tyr Thr Asp Phe Glu Lys Val Ser Gly Gln Ile Asp Pro Ser
100 105 110Val Ser Met Val Ala Arg Asp Pro Met Ile Ser Ala Tyr Pro Ile Val
115 120 125Gly Val Gln Met Glu Arg Leu Val Val Ser Lys Ser Glu Thr Ile Thr
130 135 140Gly Asp Ser Thr Lys Ser Met Ser Lys Ser Thr Ser His Ser Ser Thr145 150 155 160Asn Ile Asn Thr Val Gly Ala Glu Val Ser Gly Ser Leu Gln Leu Ala
165 170 175Gly Gly Ile Phe Pro Val Phe Ser Met Ser Ala Ser Ala Asn Tyr Ser
180 185 190His Thr Trp Gln Asn Thr Ser Thr Val Asp Asp Thr Thr Gly Glu Ser
195 200 205Phe Ser Gln Gly Leu Ser Ile Asn Thr Gly Glu Ser Ala Tyr Ile Asn
210 215 220Pro Asn Ile Arg Tyr Tyr Asn Thr Gly Thr Ala Pro Val Tyr Asn Val225 230 235 240Thr Pro Thr Thr Thr Ile Val Ile Asp Lys Gln Ser Val Ala Thr Ile
245 250 255Lys Gly Gln Glu Ser Leu Ile Gly Asp Tyr Leu Asn Pro Gly Gly Thr
260 265 270Tyr Pro Ile Ile Gly Glu Pro Pro Met Ala Leu Asn Thr Met Asp Gln
275 280 285Phe Ser Ser Arg Leu Ile Pro Ile Asn Tyr Asn Gln Leu Lys Ser Ile
290 295 300Asp Asn Gly Gly Thr Val Met Leu Ser Thr Ser Gln Phe Thr Gly Asn305 310 315 320Phe Ala Lys Tyr Asn Ser Asn Gly Asn Leu Val Thr Asp Gly Asn Asn
325 330 335Trp Gly Pro Tyr Leu Gly Thr Ile Lys Ser Thr Thr Ala Ser Leu Thr
340 345 350Leu Ser Phe Ser Gly Gln Thr Thr Gln Val Ala Val Val Ala Pro Asn
355 360 365Phe Ser Asp Pro Glu Asp Lys Thr Pro Lys Leu Thr Leu Glu Gln Ala
370 375 380Leu Val Lys Ala Phe Ala Leu Glu Lys Lys Asn Gly Lys Phe Tyr Phe385 390 395 400His Gly Leu Glu Ile Ser Lys Asn Glu Lys Ile Gln Val Phe Leu Asp
405 410 415Ser Asn Thr Asn Asn Asp Phe Glu Asn Gln Leu Lys Asn Thr Ala Asp
420 425 430Lys Asp Ile Met His Cys Ile Ile Lys Arg Asn Met Asn Ile Leu Val
435 440 445Lys Val Ile Thr Phe Lys Glu Asn Ile Ser Ser Ile Asn Ile Ile Asn
450 455 460Asp Thr Asn Phe Gly Val Gln Ser Met Thr Gly Leu Ser Asn Arg Ser465 470 475 480Lys Gly Gln Asp Gly Ile Tyr Arg Ala Ala Thr Thr Ala Phe Ser Phe
485 490 495Lys Ser Lys Glu Leu Lys Tyr Pro Glu Gly Arg Tyr Arg Met Arg Phe
500 505 510Val Ile Gln Ser Tyr Glu Pro Phe Thr Cys Asn Phe Lys Leu Phe Asn
515 520 525Asn Leu Ile Tyr Ser Ser Ser Phe Asp Lys Gly Tyr Tyr Asp Glu Phe
530 535 540Phe Tyr Phe Tyr Tyr Asn Gly Ser Lys Ser Phe Phe Asn Ile Ser Cys545 550 555 560Asp Ile Ile Asn Ser Ile Asn Arg Leu Ser Gly Val Phe Leu Ile Glu
565 570 575Leu Asp Lys Leu Ile Ile
580<210>29<211>708<212>PRT<213>蜡状芽孢杆菌<400>29Ile Asp Ser Gln Asn Gln Pro Gln Gln Val Gln Gln Asp Glu Leu Arg1 5 10 15Asn Pro Glu Phe Asn Lys Lys Glu Ser Gln Glu Phe Leu Ala Lys Pro
20 25 30Ser Lys Ile Asn Leu Phe Thr Gln Gln Met Lys Arg Glu Ile Asp Glu
35 40 45Asp Thr Asp Thr Asp Gly Asp Ser Ile Pro Asp Leu Trp Glu Glu Asn
50 55 60Gly Tyr Thr Ile Gln Asn Arg Ile Ala Val Lys Trp Asp Asp Ser Leu65 70 75 80Ala Ser Lys Gly Tyr Thr Lys Phe Val Ser Asn Pro Leu Glu Ser His
85 90 95Thr Val Gly Asp Pro Tyr Thr Asp Tyr Glu Lys Ala Ala Arg Asp Leu
100 105 110Asp Leu Ser Asn Ala Lys Glu Thr Phe Asn Pro Leu Val Ala Ala Phe
115 120 125Pro Ser Val Asn Val Ser Met Glu Lys Val Ile Leu Ser Pro Asn Glu
130 135 140Asn Leu Ser Asn Ser Val Glu Ser His Ser Ser Thr Asn Trp Ser Tyr145 150 155 160Thr Asn Thr Glu Gly Ala Ser Val Glu Ala Gly Ile Gly Pro Lys Gly
165 170 175Ile Ser Phe Gly Val Ser Val Asn Tyr Gln His Ser Glu Thr Val Ala
180 185 190Gln Glu Trp Gly Thr Ser Thr Gly Asn Thr Ser Gln Phe Asn Thr Ala
195 200 205Ser Ala Gly Tyr Leu Asn Ala Asn Val Arg Tyr Asn Asn Val Gly Thr
210 215 220Gly Ala Ile Tyr Asp Val Lys Pro Thr Thr Ser Phe Val Leu Asn Asn225 230 235 240Asp Thr Ile Ala Thr Ile Thr Ala Lys Ser Asn Ser Thr Ala Leu Asn
245 250 255Ile Ser Pro Gly Glu Ser Tyr Pro Lys Lys Gly Gln Asn Gly Ile Ala
260 265 270Ile Thr Ser Met Asp Asp Phe Asn Ser His Pro Ile Thr Leu Asn Lys
275 280 285Lys Gln Val Asp Asn Leu Leu Asn Asn Lys Pro Met Met Leu Glu Thr
290 295 300Asn Gln Thr Asp Gly Val Tyr Lys Ile Lys Asp Thr His Gly Asn Ile305 310 315 320Val Thr Gly Gly Glu Trp Asn Gly Val Ile Gln Gln Ile Lys Ala Lys
325 330 335Thr Ala Ser Ile Ile Val Asp Asp Gly Glu Arg Val Ala Glu Lys Arg
340 345 350Val Ala Ala Lys Asp Tyr Glu Asn Pro Glu Asp Lys Thr Pro Ser Leu
355 360 365Thr Leu Lys Asp Ala Leu Lys Leu Ser Tyr Pro Asp Glu Ile Lys Glu
370 375 380Ile Glu Gly Leu Leu Tyr Tyr Lys Asn Lys Pro Ile Tyr Glu Ser Ser385 390 395 400Val Met Thr Tyr Leu Asp Glu Asn Thr Ala Lys Glu Val Thr Lys Gln
405 410 415Leu Asn Asp Thr Thr Gly Lys Phe Lys Asp Val Ser His Leu Tyr Asp
420 425 430Val Lys Leu Thr Pro Lys Met Asn Val Thr Ile Lys Leu Ser Ile Leu
435 440 445Tyr Asp Asn Ala Glu Ser Asn Asp Asn Ser Ile Gly Lys Trp Thr Asn
450 455 460Thr Asn Ile Val Ser Gly Gly Asn Asn Gly Lys Lys Gln Tyr Ser Ser465 470 475 480Asn Asn Pro Asp Ala Asn Leu Thr Leu Asn Thr Asp Ala Gln Glu Lys
485 490 495Leu Asn Lys Asn Arg Asp Tyr Tyr Ile Ser Leu Tyr Met Lys Ser Glu
500 505 510Lys Asn Thr Gln Cys Glu Ile Thr Ile Asp Gly Glu Ile Tyr Pro Ile
515 520 525Thr Thr Lys Thr Val Asn Val Asn Lys Asp Asn Tyr Lys Arg Leu Asp
530 535 540Ile Ile Ala His Asn Ile Lys Ser Asn Pro Ile Ser Ser Leu His Ile545 550 555 560Lys Thr Asn Asp Glu Ile Thr Leu Phe Trp Asp Asp Ile Ser Ile Thr
565 570 575Asp Val Ala Ser Ile Lys Pro Glu Asn Leu Thr Asp Ser Glu Ile Lys
580 585 590Gln Ile Tyr Ser Arg Tyr Gly Ile Lys Leu Glu Asp Gly Ile Leu Ile
595 600 605Asp Lys Lys Gly Gly Ile His Tyr Gly Glu Phe Ile Asn Glu Ala Ser
610 615 620Phe Asn Ile Glu Pro Leu Gln Asn Tyr Val Thr Lys Tyr Glu Val Thr625 630 635 640Tyr Ser Ser Glu Leu Gly Pro Asn Val Ser Asp Thr Leu Glu Ser Asp
645 650 655Lys Ile Tyr Lys Asp Gly Thr Ile Lys Phe Asp Phe Thr Lys Tyr Ser
660 665 670Lys Asn Glu Gln Gly Leu Phe Tyr Asp Ser Gly Leu Asn Trp Asp Phe
675 680 685Lys Ile Asn Ala Ile Thr Tyr Asp Gly Lys Glu Met Asn Val Phe His
690 695 700Arg Tyr Asn Lys705<210>30<211>735<212>PRT<213>炭疽杆菌<400>30Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser1 5 10 15Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala65 70 75 80Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser145 150 155 160Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr225 230 235 240Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Gln Thr Arg Thr
275 280 285Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val305 310 315 320Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln385 390 395 400Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val465 470 475 480Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln545 550 555 560Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Val Thr Asn Ile Tyr Thr
565 570 575Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser625 630 635 640Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly705 710 715 720Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
725 730 735<210>31<211>876<212>PRT<213>艰难梭菌<400>31Met Lys Ile Gln Met Arg Asn Lys Lys Val Leu Ser Phe Leu Thr Leu1 5 10 15Thr Ala Ile Val Ser Gln Ala Leu Val Tyr Pro Val Tyr Ala Gln Thr
20 25 30Ser Thr Ser Asn His Ser Asn Lys Lys Lys Glu Ile Val Asn Glu Asp
35 40 45Ile Leu Pro Asn Asn Gly Leu Met Gly Tyr Tyr Phe Ser Asp Glu His
50 55 60Phe Lys Asp Leu Lys Leu Met Ala Pro Ile Lys Asp Gly Asn Leu Lys65 70 75 80Phe Glu Glu Lys Lys Val Asp Lys Leu Leu Asp Lys Asp Lys Ser Asp
85 90 95Val Lys Ser Ile Arg Trp Thr Gly Arg Ile Ile Pro Ser Lys Asp Gly
100 105 110Glu Tyr Thr Leu Ser Thr Asp Arg Asp Asp Val Leu Met Gln Val Asn
115 120 125Thr Glu Ser Thr Ile Ser Asn Thr Leu Lys Val Asn Met Lys Lys Gly
130 135 140Lys Glu Tyr Lys Val Arg Ile Glu Leu Gln Asp Lys Asn Leu Gly Ser145 150 155 160Ile Asp Asn Leu Ser Ser Pro Asn Leu Tyr Trp Glu Leu Asp Gly Met
165 170 175Lys Lys Ile Ile Pro Glu Glu Asn Leu Phe Leu Arg Asp Tyr Ser Asn
180 185 190Ile Glu Lys Asp Asp Pro Phe Ile Pro Asn Asn Asn Phe Phe Asp Pro
195 200 205Lys Leu Met Ser Asp Trp Glu Asp Glu Asp Leu Asp Thr Asp Asn Asp
210 215 220Asn lle Pro Asp Ser Tyr Glu Arg Asn Gly Tyr Thr Ile Lys Asp Leu225 230 235 240Ile Ala Val Lys Trp Glu Asp Ser Phe Ala Glu Gln Gly Tyr Lys Lys
245 250 255Tyr Val Ser Asn Tyr Leu Glu Ser Asn Thr Ala Gly Asp Pro Tyr Thr
260 265 270Asp Tyr Glu Lys Ala Ser Gly Ser Phe Asp Lys Ala Ile Lys Thr Glu
275 280 285Ala Arg Asp Pro Leu Val Ala Ala Tyr Pro Ile Val Gly Val Gly Met
290 295 300Glu Lys Leu Ile Ile Ser Thr Asn Glu His Ala Ser Thr Asp Gln Gly305 310 315 320Lys Thr Val Ser Arg Ala Thr Thr Asn Ser Lys Thr Glu Ser Asn Thr
325 330 335Ala Gly Val Ser Val Asn Val Gly Tyr Gln Asn Gly Phe Thr Ala Asn
340 345 350ValThr Thr Asn Tyr Ser His Thr Thr Asp Asn Ser Thr Ala Val Gln
355 360 365Asp Ser Asn Gly Glu Ser Trp Asn Thr Gly Leu Ser Ile Asn Lys Gly
370 375 380Glu Ser Ala Tyr Ile Asn Ala Asn Val Arg Tyr Tyr Asn Thr Gly Thr385 390 395 400Ala Pro Met Tyr Lys Val Thr Pro Thr Thr Asn Leu Val Leu Asp Gly
405 410 415Asp Thr Leu Ser Thr Ile Lys Ala Gln Glu Asn Gln Ile Gly Asn Asn
420 425 430Leu Ser Pro Gly Asp Thr Tyr Pro Lys Lys Gly Leu Ser Pro Leu Ala
435 440 445Leu Asn Thr Met Asp Gln Phe Ser Ser Arg Leu Ile Pro Ile Asn Tyr
450 455 460Asp Gln Leu Lys Lys Leu Asp Ala Gly Lys Gln Ile Lys Leu Glu Thr465 470 475 480Thr Gln Val Ser Gly Asn Phe Gly Thr Lys Asn Ser Ser Gly Gln Ile
485 490 495Val Thr Glu Gly Asn Ser Trp Ser Asp Tyr Ile Ser Gln Ile Asp Ser
500 505 510Ile Ser Ala Ser Ile Ile Leu Asp Thr Glu Asn Glu Ser Tyr Glu Arg
515 520 525Arg Val Thr Ala Lys Asn Leu Gln Asp Pro Glu Asp Lys Thr Pro Glu
530 535 540Leu Thr Ile Gly Glu Ala Ile Glu Lys Ala Phe Gly Ala Thr Lys Lys545 550 555 560Asp Gly Leu Leu Tyr Phe Asn Asp Ile Pro Ile Asp Glu Ser Cys Val
565 570 575Glu Leu Ile Phe Asp Asp Asn Thr Ala Asn Lys Ile Lys Asp Ser Leu
580 585 590Lys Thr Leu Ser Asp Lys Lys Ile Tyr Asn Val Lys Leu Glu Arg Gly
595 600 605Met Asn Ile Leu Ile Lys Thr Pro Thr Tyr Phe Thr Asn Phe Asp Asp
610 615 620Tyr Asn Asn Tyr Pro Ser Thr Trp Ser Asn Val Asn Thr Thr Asn Gln625 630 635 640Asp Gly Leu Gln Gly Ser Ala Asn Lys Leu Asn Gly Glu Thr Lys Ile
645 650 655Lys Ile Pro Met Ser Glu Leu Lys Pro Tyr Lys Arg Tyr Val Phe Ser
660 665 670Gly Tyr Ser Lys Asp Pro Leu Thr Ser Asn Ser Ile Ile Val Lys Ile
675 680 685Lys Ala Lys Glu Glu Lys Thr Asp Tyr Leu Val Pro Glu Gln Gly Tyr
690 695 700Thr Lys Phe Ser Tyr Glu Phe Glu Thr Thr Glu Lys Asp Ser Ser Asn705 710 715 720Ile Glu Ile Thr Leu Ile Gly Ser Gly Thr Thr Tyr Leu Asp Asn Leu
725 730 735Ser Ile Thr Glu Leu Asn Ser Thr Pro Glu Ile Leu Asp Glu Pro Glu
740 745 750Val Lys Ile Pro Thr Asp Gln Glu Ile Met Asp Ala His Lys Ile Tyr
755 760 765Phe Ala Asp Leu Asn Phe Asn Pro Ser Thr Gly Asn Thr Tyr Ile Asn
770 775 780Gly Met Tyr Phe Ala Pro Thr Gln Thr Asn Lys Glu Ala Leu Asp Tyr785 790 795 800Ile Gln Lys Tyr Arg Val Glu Ala Thr Leu Gln Tyr Ser Gly Phe Lys
805 810 815Asp Ile Gly Thr Lys Asp Lys Glu Met Arg Asn Tyr Leu Gly Asp Pro
820 825 830Asn Gln Pro Lys Thr Asn Tyr Val Asn Leu Arg Ser Tyr Phe Thr Gly
835 840 845Gly Glu Asn Ile Met Thr Tyr Lys Lys Leu Arg Ile Tyr Ala Ile Thr
850 855 860Pro Asp Asp Arg Glu Leu Leu Val Leu Ser Val Asp865 870 875<210>32<211>875<212>PRT<213>产气荚膜梭菌<400>32Met Asn Ile Gln Ile Lys Asn Val Phe Ser Phe Leu Thr Leu Thr Ala1 5 10 15Met Ile Ser Gln Thr Leu Ser Tyr Asn Val Tyr Ala Gln Thr Thr Thr
20 25 30Gln Asn Asp Thr Asn Gln Lys Glu Glu Ile Thr Asn Glu Asn Thr Leu
35 40 45Ser Ser Asn Gly Leu Met Gly Tyr Tyr Phe Ala Asp Glu His Phe Lys
50 55 60Asp Leu Glu Leu Met Ala Pro Ile Lys Asn Gly Asp Leu Lys Phe Glu65 70 75 80Glu Lys Lys Val Asp Lys Leu Leu Thr Glu Asp Asn Ser Ser Ile Lys
85 90 95Ser Ile Arg Trp Thr Gly Arg Ile Ile Pro Ser Glu Asp Gly Glu Tyr
100 105 110Ile Leu Ser Thr Asp Arg Asn Asp Val Leu Met Gln Ile Asn Ala Lys
115 120 125Gly Asp Ile Ala Lys Thr Leu Lys Val Asn Met Lys Lys Gly Gln Ala
130 135 140Tyr Asn Ile Arg Ile Glu Ile Gln Asp Lys Asn Leu Gly Ser Ile Asp145 150 155 160Asn Leu Ser Val Pro Lys Leu Tyr Trp Glu Leu Asn Gly Asn Lys Thr
165 170 175Val Ile Pro Glu Glu Asn Leu Phe Phe Arg Asp Tyr Ser Lys Ile Asp
180 185 190Glu Asn Asp Pro Phe Ile Pro Asn Asn Asn Phe Phe Asp Val Arg Phe
195 200 205Phe Ser Ala Ala Trp Glu Asp Glu Asp Leu Asp Thr Asp Asn Asp Asn
210 215 220Ile Pro Asp Ala Tyr Glu Lys Asn Gly Tyr Thr Ile Lys Asp Ser Ile225 230 235 240Ala Val Lys Trp Asn Asp Ser Phe Ala Glu Gln Gly Tyr Lys Lys Tyr
245 250 255Val Ser Ser Tyr Leu Glu Ser Asn Thr Ala Gly Asp Pro Tyr Thr Asp
260 265 270Tyr Gln Lys Ala Ser Gly Ser Ile Asp Lys Ala Ile Lys Leu Glu Ala
275 280 285Arg Asp Pro Leu Val Ala Ala Tyr Pro Val Val Gly Val Gly Met Glu
290 295 300Asn Leu Ile Ile Ser Thr Asn Glu His Ala Ser Ser Asp Gln Gly Lys305 310 315 320Thr Val Ser Arg Ala Thr Thr Asn Ser Lys Thr Asp Ala Asn Thr Val
325 330 335Gly Val Ser Ile Ser Ala Gly Tyr Gln Asn Gly Phe Thr Gly Asn Ile
340 345 350Thr Thr Ser Tyr Ser His Thr Thr Asp Asn Ser Thr Ala Val Gln Asp
355 360 365Ser Asn Gly Glu Ser Trp Asn Thr Gly Leu Ser Ile Asn Lys Gly Glu
370 375 380Ser Ala Tyr Ile Asn Ala Asn Val Arg Tyr Tyr Asn Thr Gly Thr Ala385 390 395 400Pro Met Tyr Lys Val Thr Pro Thr Thr Asn Leu Val Leu Asp Gly Glu
405 410 415Thr Leu Ala Thr Ile Lys Ala Gln Asp Asn Gln Ile Gly Asn Asn Leu
420 425 430Ser Pro Asn Glu Thr Tyr Pro Lys Lys Gly Leu Ser Pro Leu Ala Leu
435 440 445Asn Thr Met Asp Gln Phe Asn Ala Arg Leu Ile Pro Ile Asn Tyr Asp
450 455 460Gln Leu Lys Lys Leu Asp Ser Gly Lys Gln Ile Lys Leu Glu Thr Thr465 470 475 480Gln Val Ser Gly Asn Tyr Gly Thr Lys Asn Ser Gln Gly Gln Ile Ile
485 490 495Thr Glu Gly Asn Ser Trp Ser Asn Tyr Ile Ser Gln Ile Asp Ser Val
500 505 510Ser Ala Ser Ile Ile Leu Asp Thr Gly Ser Gln Thr Phe Glu Arg Arg
515 520 525Val Ala Ala Lys Glu Gln Gly Asn Pro Glu Asp Lys Thr Pro Glu Ile
530 535 540Thr Ile Gly Glu Ala Ile Lys Lys Ala Phe Ser Ala Thr Lys Asn Gly545 550 555 560Glu Leu Leu Tyr Phe Asn Gly Ile Pro Ile Asp Glu Ser Cys Val Glu
565 570 575Leu Ile Phe Asp Asp Asn Thr Ser Glu Ile Ile Lys Glu Gln Leu Lys
580 585 590Tyr Leu Asp Asp Lys Lys Ile Tyr Asn Val Lys Leu Glu Arg Gly Met
595 600 605Asn Ile Leu Ile Lys Val Pro Ser Tyr Phe Thr Asn Phe Asp Glu Tyr
610 615 620Asn Asn Phe Pro Ala Ser Trp Ser Asn Ile Asp Thr Lys Asn Gln Asp625 630 635 640Gly Leu Gln Ser Val Ala Asn Lys Leu Ser Gly Glu Thr Lys Ile Ile
645 650 655Ile Pro Met Ser Lys Leu Lys Pro Tyr Lys Arg Tyr Val Phe Ser Gly
660 665 670Tyr Ser Lys Asp Pro Ser Thr Ser Asn Ser Ile Thr Val Asn Ile Lys
675 680 685Ser Lys Glu Gln Lys Thr Asp Tyr Leu Val Pro Glu Lys Asp Tyr Thr
690 695 700Lys Phe Ser Tyr Glu Phe Glu Thr Thr Gly Lys Asp Ser Ser Asp Ile705 710 715 720Glu Ile Thr Leu Thr Ser Ser Gly Val Ile Phe Leu Asp Asn Leu Ser
725 730 735Ile Thr Glu Leu Asn Ser Thr Pro Glu Ile Leu Lys Glu Pro Glu Ile
740 745 750Lys Val Pro Ser Asp Gln Glu Ile Leu Asp Ala His Asn Lys Tyr Tyr
755 760 765Ala Asp Ile Lys Leu Asp Thr Asn Thr Gly Asn Thr Tyr Ile Asp Gly
770 775 780Ile Tyr Phe Glu Pro Thr Gln Thr Asn Lys Glu Ala Leu Asp Tyr Ile785 790 795 800Gln Lys Tyr Arg Val Glu Ala Thr Leu Gln Tyr Ser Gly Phe Lys Asp
805 810 815Ile Gly Thr Lys Asp Lys Glu Ile Arg Asn Tyr Leu Gly Asp Gln Asn
820 825 830Gln Pro Lys Thr Asn Tyr Ile Asn Phe Arg Ser Tyr Phe Thr Ser Gly
835 840 845Glu Asn Val Met Thr Tyr Lys Lys Leu Arg Ile Tyr Ala Val Thr Pro
850 855 860Asp Asn Arg Glu Leu Leu Val Leu Ser Val Asn865 870 875<210>33<211>879<212>PRT<213>螺状梭菌<400>33Met Lys Asn Lys Lys Ile Leu Gly Leu Leu Thr Cys Thr Val Leu Val1 5 10 15Gly Gln Met Met Thr Tyr Pro Val Tyr Ala Lys Thr Ile Thr Gln Asn
20 25 30Tyr Asp Asn Gln Glu Val Glu Thr Thr Asn Glu Lys Thr Val Ser Ser
35 40 45Asn Gly Leu Met Gly Tyr Tyr Phe Ala Asp Glu His Phe Lys Asp Leu
50 55 60Glu Leu Met Ala Pro Val Lys Asn Gly Glu Leu Lys Phe Glu Lys Asn65 70 75 80Lys Val Glu Lys Leu Leu Thr Glu Glu Lys Thr Asn Ile Lys Ser Ile
85 90 95Arg Trp Thr Gly Arg Ile Ile Pro Ser Lys Asp Gly Glu Tyr Thr Leu
100 105 110Ser Thr Asp Lys Asp Asn Val Leu Met Gln Ile Asn Ala Glu Gly Glu
115 120 125Ile Ala Asn Thr Leu Lys Val Asn Met Ile Lys Gly Gln Glu Tyr Ser
130 135 140Ile Arg Ile Glu Ile Gln Asp Lys Asp Ile Gly Tyr Val Asp Asp Leu145 150 155 160Ser Ser Pro Lys Leu Tyr Trp Glu Leu Asn Gly Asp Lys Thr Leu Ile
165 170 175Pro Glu Lys Asn Leu Phe Leu Arg Asp Tyr Ser Lys Ile Asp Glu Asn
180 185 190Asp Pro Phe Ile Pro Lys Asp Asn Phe Phe Asp Leu Lys Leu Lys Ser
195 200 205Arg Ser Ala Arg Leu Ala Ser Gly Trp Gly Asp Glu Asp Leu Asp Thr
210 215 220Asp Asn Asp Asn Ile Pro Asp Ala Tyr Glu Lys Asn Gly Tyr Thr Ile225 230 235 240Lys Asp Ser Ile Ala Val Lys Trp Glu Asp Ser Phe Ala Gln Gln Gly
245 250 255Tyr Lys Lys Tyr Leu Ser Ser Tyr Leu Glu Ser Asn Thr Ala Gly Asp
260 265 270Pro Tyr Thr Asp Tyr Gln Lys Ala Ser Gly Ser Phe Asp Lys Ala Ile
275 280 285Lys Ala Glu Ala Arg Asp Pro Leu Val Ala Ala Tyr Pro Val Val Gly
290 295 300Val Gly Met Glu Lys Leu Ile Ile Ser Thr Asn Glu His Ala Ser Thr305 310 315 320Asp Gln Gly Lys Thr Val Ser Arg Asn Thr Thr Asn Ser Lys Thr Asp
325 330 335Ala Asn Thr Ala Gly Val Ala Ile Asn Ile Ala Tyr Gln Asn Gly Phe
340 345 350Thr Gly Ser Ile Thr Thr Asn Tyr Ser His Thr Thr Glu Asn Ser Thr
355 360 365Ala Val Gln Asn Ser Asn Gly Glu Ser Trp Asn Thr Ser Leu Ser Ile
370 375 380Asn Lys Gly Glu Ser Ala Tyr Ile Asn Ala Asn Val Arg Tyr Tyr Asn385 390 395 400Thr Gly Thr Ala Pro Met Tyr Lys Val Thr Pro Thr Thr Asn Leu Val
405 410 415Leu Asp Gly Asp Thr Leu Thr Thr Ile Lys Ala Gln Asp Asn Gln Ile
420 425 430Gly Asn Asn Leu Ser Pro Asn Glu Thr Tyr Pro Lys Lys Gly Leu Ser
435 440 445Pro Leu Ala Leu Asn Thr Met Asp Gln Phe Ser Ser Arg Leu Ile Pro
450 455 460Ile Asn Tyr Asp Gln Leu Lys Lys Leu Asp Ala Gly Lys Gln Ile Lys465 470 475 480Leu Glu Thr Thr Gln Val Ser Gly Asn Tyr Gly Ile Lys Asn Ser Gln
485 490 495Gly Gln Ile Ile Thr Glu Gly Asn Ser Trp Ser Asp Tyr Ile Ser Gln
500 505 510Ile Asp Ser Leu Ser Ala Ser Ile Ile Leu Asp Thr Gly Ser Asp Val
515 520 525Phe Glu Arg Arg Val Thr Ala Lys Asp Ser Ser Asn Pro Glu Asp Lys
530 535 540Thr Pro Val Leu Thr Ile Gly Glu Ala Ile Glu Lys Ala Phe Gly Ala545 550 555 560Thr Lys Asn Gly Glu Ile Leu Tyr Phe Asn Gly Met Pro Ile Asp Glu
565 570 575Ser Cys Val Glu Leu Ile Phe Asp Gly Asn Thr Ala Asn Leu Ile Lys
580 585 590Glu Arg Leu Asn Ala Leu Asn Asp Lys Lys Ile Tyr Asn Val Gln Leu
595 600 605Glu Arg Gly Met Lys Ile Leu Ile Lys Thr Ser Thr Tyr Phe Asn Asn
610 615 620Phe Asp Gly Tyr Asn Asn Phe Pro Ser Ser Trp Ser Asn Val Asp Ser625 630 635 640Asn Asn Gln Asp Gly Leu Gln Asn Ala Ala Asn Lys Leu Ser Gly Glu
645 650 655Thr Lys Ile Val Ile Pro Met Ser Lys Leu Asn Pro Tyr Lys Arg Tyr
660 665 670Val Phe Ser Gly Tyr Leu Lys Asn Ser Ser Thr Ser Asn Pro Ile Thr
675 680 685Val Asn Ile Lys Ala Lys Glu Gln Lys Thr Tyr Asn Leu Val Ser Glu
690 695 700Asn Asp Tyr Lys Lys Phe Ser Tyr Glu Phe Glu Thr Ile Gly Arg Asp705 710 715 720Ala Ser Asn Ile Glu Ile Thr Leu Thr Ser Ser Gly Thr Ile Phe Leu
725 730 735Asp Asn Leu Ser Ile Thr Glu Leu Asn Ser Thr Pro Glu Ile Leu Lys
740 745 750Glu Pro Asp Ile Lys Val Pro Ser Asp Gln Glu Ile Ile Asp Ala His
755 760 765Lys Lys Tyr Tyr Ala Asp Leu Ser Phe Asn Gln Ser Thr Ala Asn Tyr
770 775 780Tyr Leu Asp Gly Leu Tyr Phe Glu Pro Thr Gln Thr Asn Lys Glu Val785 790 795 800Leu Asp Tyr Ile Gln Lys Tyr Lys Val Glu Ala Thr Leu Glu Tyr Ser
805 810 815Gly Phe Lys Asp Ile Gly Thr Lys Asp Lys Glu Leu Arg Asn Tyr Thr
820 825 830Gly Asp Ser Asn Gln Pro Lys Thr Asn Tyr Val Asn Phe Arg Ser Tyr
835 840 845Phe Thr Ser Gly Glu Asn Val Met Pro Tyr Lys Lys Leu Arg Ile Tyr
850 855 860Ala Ile Thr Pro Glu Asn Lys Glu Leu Leu Val Leu Ser Ile Asn865 870 875<210>34<211>721<212>PRT<213>肉毒梭菌<400>34Met Leu Val Ser Lys Phe Glu Asn Ser Val Lys Asn Ser Asn Lys Asn1 5 10 15Tyr Phe Thr Ile Asn Gly Leu Met Gly Tyr Tyr Phe Glu Asn Asp Phe
20 25 30Phe Asn Leu Asn Ile Ile Ser Pro Thr Leu Asp Gly Asn Leu Thr Phe
35 40 45Ser Lys Glu Asp Ile Asn Ser Ile Leu Gly Asn Lys Ile Ile Lys Ser
50 55 60Ala Arg Trp Ile Gly Leu Ile Lys Pro Ser Ile Thr Gly Glu Tyr Ile65 70 75 80Leu Ser Thr Asn Ser Pro Asn Cys Arg Val Glu Leu Asn Gly Glu Ile
85 90 95Phe Asn Leu Ser Leu Asn Thr Ser Asn Thr Val Asn Leu Ile Gln Gly
100 105 110Asn Val Tyr Asp Ile Arg Ile Glu Gln Leu Met Ser Glu Asn Gln Leu
115 120 125Leu Lys Asn Tyr Glu Gly Ile Lys Leu Tyr Trp Glu Thr Ser Asp Ile
130 135 140Ile Lys Glu Ile Ile Pro Ser Glu Val Leu Leu Lys Pro Asn Tyr Ser145 150 155 160Asn Thr Asn Glu Lys Ser Lys Phe Ile Pro Asn Asn Thr Leu Phe Ser
165 170 175Asn Ala Lys Leu Lys Ala Asn Ala Asn Arg Asp Thr Asp Arg Asp Gly
180 185 190Ile Pro Asp Glu Trp Glu Ile Asn Gly Tyr Thr Val Met Asn Gln Lys
195 200 205Ala Val Ala Trp Asp Asp Lys Phe Ala Ala Asn Gly Tyr Lys Lys Tyr
210 215 220Val Ser Asn Pro Phe Lys Pro Cys Thr Ala Asn Asp Pro Tyr Thr Asp225 230 235 240Phe Glu Lys Val Ser Gly Gln Ile Asp Pro Ser Val Ser Met Val Ala
245 250 255Arg Asp Pro Met Ile Ser Ala Tyr Pro Ile Val Gly Val Gln Met Glu
260 265 270Arg Leu Val Val Ser Lys Ser Glu Thr Ile Thr Gly Asp Ser Thr Lys
275 280 285Ser Met Ser Lys Ser Thr Ser His Ser Ser Thr Asn Ile Asn Thr Val
290 295 300Gly Ala Glu Val Ser Gly Ser Leu Gln Leu Ala Gly Gly Ile Phe Pro305 310 315 320Val Phe Ser Met Ser Ala Ser Ala Asn Tyr Ser His Thr Trp Gln Asn
325 330 335Thr Ser Thr Val Asp Asp Thr Thr Gly Glu Ser Phe Ser Gln Gly Leu
340 345 350Ser Ile Asn Thr Gly Glu Ser Ala Tyr Ile Asn Pro Asn Ile Arg Tyr
355 360 365Tyr Asn Thr Gly Thr Ala Pro Val Tyr Asn Val Thr Pro Thr Thr Thr
370 375 380Ile Val Ile Asp Lys Gln Ser Val Ala Thr Ile Lys Gly Gln Glu Ser385 390 395 400Leu Ile Gly Asp Tyr Leu Asn Pro Gly Gly Thr Tyr Pro Ile Ile Gly
405 410 415Glu Pro Pro Met Ala Leu Asn Thr Met Asp Gln Phe Ser Ser Arg Leu
420 425 430Ile Pro Ile Asn Tyr Asn Gln Leu Lys Ser Ile Asp Asn Gly Gly Thr
435 440 445Val Met Leu Ser Thr Ser Gln Phe Thr Gly Asn Phe Ala Lys Tyr Asn
450 455 460Ser Asn Gly Asn Leu Val Thr Asp Gly Asn Asn Trp Gly Pro Tyr Leu465 470 475 480Gly Thr Ile Lys Ser Thr Thr Ala Ser Leu Thr Leu Ser Phe Ser Gly
485 490 495Gln Thr Thr Gln Val Ala Val Val Ala Pro Asn Phe Ser Asp Pro Glu
500 505 510Asp Lys Thr Pro Lys Leu Thr Leu Glu Gln Ala Leu Val Lys Ala Phe
515 520 525Ala Leu Glu Lys Lys Asn Gly Lys Phe Tyr Phe His Gly Leu Glu Ile
530 535 540Ser Lys Asn Glu Lys Ile Gln Val Phe Leu Asp Ser Asn Thr Asn Asn545 550 555 560Asp Phe Glu Asn Gln Leu Lys Asn Thr Ala Asp Lys Asp Ile Met His
565 570 575Cys Ile Ile Lys Arg Asn Met Asn Ile Leu Val Lys Val Ile Thr Phe
580 585 590Lys Glu Asn Ile Ser Ser Ils Asn Ile Ile Asn Asp Thr Asn Phe Gly
595 600 605Val Gln Ser Met Thr Gly Leu Ser Asn Arg Ser Lys Gly Gln Asp Gly
610 615 620Ile Tyr Arg Ala Ala Thr Thr Ala Phe Ser Phe Lys Ser Lys Glu Leu625 630 635 640Lys Tyr Pro Glu Gly Arg Tyr Arg Met Arg Phe Val Ile Gln Ser Tyr
645 650 655Glu Pro Phe Thr Cys Asn Phe Lys Leu Phe Asn Asn Leu Ile Tyr Ser
660 665 670Ser Ser Phe Asp Lys Gly Tyr Tyr Asp Glu Phe Phe Tyr Phe Tyr Tyr
675 680 685Asn Gly Ser Lys Ser Phe Phe Asn Ile Ser Cys Asp Ile Ile Asn Ser
690 695 700Ile Asn Arg Leu Ser Gly Val Phe Leu Ile Glu Leu Asp Lys Leu Ile705 710 715 720Ile<210>35<211>1338<212>PRT<213>蜡状芽孢杆菌<400>35Met Lys Arg Met Glu Gly Lys Leu Phe Met Val Ser Lys Lys Leu Gln 1 5 10 15Val Val Thr Lys Thr Val Leu Leu Ser Thr Val Phe Ser Ile Ser Leu
20 25 30Leu Asn Asn Glu Val Ile Lys Ala Glu Gln Leu Asn Ile Asn Ser Gln
35 40 45Ser Lys Tyr Thr Asn Leu Gln Asn Leu Lys Ile Thr Asp Lys Val Glu
50 55 60Asp Phe Lys Glu Asp Lys Glu Lys Ala Lys Glu Trp Gly Lys Glu Lys65 70 75 80Glu Lys Glu Trp Lys Leu Thr Ala Thr Glu Lys Gly Lys Met Asn Asn
85 90 95Phe Leu Asp Asn Lys Asn Asp Ile Lys Thr Asn Tyr Lys Glu Ile Thr
100 105 110Phe Ser Ile Ala Gly Ser Phe Glu Asp Glu Ile Lys Asp Leu Lys Glu
115 120 125Ile Asp Lys Met Phe Asp Lys Thr Asn Leu Ser Asn Ser Ile Ile Thr130 135 140Tyr Lys Asn Val Glu Pro Thr Thr Ile Gly Phe Asn Lys Ser Leu Thr145 150 155 160Glu Gly Asn Thr Ile Asn Ser Asp Ala Met Ala Gln Phe Lys Glu Gln
165 170 175Phe Leu Asp Arg Asp Ile Lys Phe Asp Ser Tyr Leu Asp Thr His Leu
180 185 190Thr Ala Gln Gln Val Ser Ser Lys Glu Arg Val Ile Leu Lys Val Thr
195 200 205Val Pro Ser Gly Lys Gly Ser Thr Thr Pro Thr Lys Ala Gly Val Ile
210 215 220Leu Asn Asn Ser Glu Tyr Lys Met Leu Ile Asp Asn Gly Tyr Met Val225 230 235 240His Val Asp Lys Val Ser Lys Val Val Lys Lys Gly Val Glu Cys Leu
245 250 255Gln Ile Glu Gly Thr Leu Lys Lys Ser Leu Asp Phe Lys Asn Asp Ile
260 265 270Asn Ala Glu Ala His Ser Trp Gly Met Lys Asn Tyr Glu Glu Trp Ala
275 280 285Lys Asp Leu Thr Asp Ser Gln Arg Glu Ala Leu Asp Gly Tyr Ala Arg
290 295 300Gln Asp Tyr Lys Glu Ile Asn Asn Tyr Leu Arg Asn Gln Gly Gly Ser305 310 315 320Gly Asn Glu Lys Leu Asp Ala Gln Ile Lys Asn Ile Ser Asp Ala Leu
325 330 335Gly Lys Lys Pro Ile Pro Glu Asn Ile Thr Val Tyr Arg Trp Cys Gly
340 345 350Met Pro Glu Phe Gly Tyr Gln Ile Ser Asp Pro Leu Pro Ser Leu Lys
355 360 365Asp Phe Glu Glu Gln Phe Leu Asn Thr Ile Lys Glu Asp Lys Gly Tyr
370 375 380Met Ser Thr Ser Leu Ser Ser Glu Arg Leu Ala Ala Phe Gly Ser Arg385 390 395 400Lys Ile Ile Leu Arg Leu Gln Val Pro Lys Gly Ser Thr Gly Ala Tyr
405 410 415Leu Ser Ala Ile Gly Gly Phe Ala Ser Glu Lys Glu Ile Leu Leu Asp
420 425 430Lys Asp Ser Lys Tyr His Ile Asp Lys Val Thr Glu Val Ile Ile Lys
435 440 445Gly Val Lys Arg Tyr Val Val Asp Ala Thr Leu Leu Thr Asn Ser Arg
450 455 460Gly Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr Pro465 470 475 480Ser Asp Ile Gly Ser Thr Met Lys Thr Asn Gln Ile Ser Thr Thr Gln
485 490 495Lys Asn Gln Gln Lys Glu Met Asp Arg Lys Gly Leu Leu Gly Tyr Tyr
500 505 510Phe Lys Gly Lys Asp Phe Ser Asn Leu Thr Met Phe Ala Pro Thr Arg
515 520 525Asp Ser Thr Leu Ile Tyr Asp Gln Gln Thr Ala Asn Lys Leu Leu Asp
530 535 540Lys Lys Gln Gln Glu Tyr Gln Ser Ile Arg Trp Ile Gly Leu Ile Gln545 550 555 560Ser Lys Glu Thr Gly Asp Phe Thr Phe Asn Leu Ser Glu Asp Glu Gln
565 570 575Ala Ile Ile Glu Ile Asn Gly Lys Ile Ile Ser Asn Lys Gly Lys Glu
580 585 590Lys Gln Val Val His Leu Glu Lys Gly Lys Leu Val Pro Ile Lys Ile
595 600 605Glu Tyr Gln Ser Asp Thr Lys Phe Asn Ile Asp Ser Lys Thr Phe Lys
610 615 620Glu Leu Lys Leu Phe Lys Ile Asp Ser Gln Asn Gln Pro Gln Gln Val625 630 635 640Gln Gln Asp Glu Leu Arg Asn Pro Glu Phe Asn Lys Lys Glu Ser Gln
645 650 655Glu Phe Leu Ala Lys Pro Ser Lys Ile Asn Leu Phe Thr Gln Gln Met
660 665 670Lys Arg Glu Ile Asp Glu Asp Thr Asp Thr Asp Gly Asp Ser Ile Pro
675 680 685Asp Leu Trp Glu Glu Asn Gly Tyr Thr Ile Gln Asn Arg Ile Ala Val
690 695 700Lys Trp Asp Asp Ser Leu Ala Ser Lys Gly Tyr Thr Lys Phe Val Ser705 710 715 720Asn Pro Leu Glu Ser His Thr Val Gly Asp Pro Tyr Thr Asp Tyr Glu
725 730 735Lys Ala Ala Arg Asp Leu Asp Leu Ser Asn Ala Lys Glu Thr Phe Asn
740 745 750Pro Leu Val Ala Ala Phe Pro Ser Val Asn Val Ser Met Glu Lys Val
755 760 765Ile Leu Ser Pro Asn Glu Asn Leu Ser Asn Ser Val Glu Ser His Ser
770 775 780Ser Thr Asn Trp Ser Tyr Thr Asn Thr Glu Gly Ala Ser Val Glu Ala785 790 795 800Gly Ile Gly Pro Lys Gly Ile Ser Phe Gly Val Ser Val Asn Tyr Gln
805 810 815His Ser Glu Thr Val Ala Gln Glu Trp Gly Thr Ser Thr Gly Asn Thr
820 825 830Ser Gln Phe Asn Thr Ala Ser Ala Gly Tyr Leu Asn Ala Asn Val Arg
835 840 845Tyr Asn Asn Val Gly Thr Gly Ala Ile Tyr Asp Val Lys Pro Thr Thr
850 855 860Ser Phe Val Leu Asn Asn Asp Thr Ile Ala Thr Ile Thr Ala Lys Ser865 870 875 880Asn Ser Thr Ala Leu Asn Ile Ser Pro Gly Glu Ser Tyr Pro Lys Lys
885 890 895Gly Gln Asn Gly Ile Ala Ile Thr Ser Met Asp Asp Phe Asn Ser His
900 905 910Pro Ile Thr Leu Asn Lys Lys Gln Val Asp Asn Leu Leu Asn Asn Lys
915 920 925Pro Met Met Leu Glu Thr Asn Gln Thr Asp Gly Val Tyr Lys Ile Lys
930 935 940Asp Thr His Gly Asn Ile Val Thr Gly Gly Glu Trp Asn Gly Val Ile945 950 955 960Gln Gln Ile Lys Ala Lys Thr Ala Ser Ile Ile Val Asp Asp Gly Glu
965 970 975Arg Val Ala Glu Lys Arg Val Ala Ala Lys Asp Tyr Glu Asn Pro Glu
980 985 990Asp Lys Thr Pro Ser Leu Thr Leu Lys Asp Ala Leu Lys Leu Ser Tyr
995 1000 1005Pro Asp Glu Ile Lys Glu Ile Glu Gly Leu Leu Tyr Tyr Lys Asn Lys
1010 1015 1020Pro Ile Tyr Glu Ser Ser Val Met Thr Tyr Leu Asp Glu Asn Thr Ala1025 1030 1035 1040Lys Glu Val Thr Lys Gln Leu Asn Asp Thr Thr Gly Lys Phe Lys Asp
1045 1050 1055Val Ser His Leu Tyr Asp Val Lys Leu Thr Pro Lys Met Asn Val Thr
1060 1065 1070Ile Lys Leu Ser Ile Leu Tyr Asp Asn Ala Glu Ser Asn Asp Asn Ser
1075 1080 1085Ile Gly Lys Trp Thr Asn Thr Asn Ile Val Ser Gly Gly Asn Asn Gly
1090 1095 1100Lys Lys Gln Tyr Ser Ser Asn Asn Pro Asp Ala Asn Leu Thr Leu Asn1105 1110 1115 1120Thr Asp Ala Gln Glu Lys Leu Asn Lys Asn Arg Asp Tyr Tyr Ile Ser
1125 1130 1135Leu Tyr Met Lys Ser Glu Lys Asn Thr Gln Cys Glu Ile Thr Ile Asp
1140 1145 1150Gly Glu Ile Tyr Pro Ile Thr Thr Lys Thr Val Asn Val Asn Lys Asp
1155 1160 1165Asn Tyr Lys Arg Leu Asp Ile Ile Ala His Asn Ile Lys Ser Asn Pro
1170 1175 1180Ile Ser Ser Leu His Ile Lys Thr Asn Asp Glu Ile Thr Leu Phe Trp1185 1190 1195 1200Asp Asp Ile Ser Ile Thr Asp Val Ala Ser Ile Lys Pro Glu Asn Leu
1205 1210 1215Thr Asp Ser Glu Ile Lys Gln Ile Tyr Ser Arg Tyr Gly Ile Lys Leu
1220 1225 1230Glu Asp Gly Ile Leu Ile Asp Lys Lys Gly Gly Ile His Tyr Gly Glu
1235 1240 1245Phe Ile Asn Glu Ala Ser Phe Asn Ile Glu Pro Leu Gln Asn Tyr Val1250 1255 1260Thr Lys Tyr Glu Val Thr Tyr Ser Ser Glu Leu Gly Pro Asn Val Ser1265 1270 1275 1280Asp Thr Leu Glu Ser Asp Lys Ile Tyr Lys Asp Gly Thr Ile Lys Phe
1285 1290 1295Asp Phe Thr Lys Tyr Ser Lys Asn Glu Gln Gly Leu Phe Tyr Asp Ser
1300 1305 1310Gly Leu Asn Trp Asp Phe Lys Ile Asn Ala Ile Thr Tyr Asp Gly Lys
1315 1320 1325Glu Met Asn Val Phe His Arg Tyr Asn Lys
1330 1335
Claims (27)
1.由两组分组成的孔形成A-B毒素的B组分,其中所述的B组分包括抑制其孔形成能力的突变,其中所述的突变不是炭疽保护性抗原(SEQID NO.12)第302-325位氨基酸的缺失。
2.如权利要求1所述的B组分,其中所述的B组分是炭疽保护性抗原。
3 如权利要求1所述的B组分,其中所述的B组分缺乏孔-形成能力。
4.如权利要求1所述的B组分,其中所述的B组分具有与SEQ ID No.:21有至少80%同一性的氨基酸序列,并具有选自下述的替换:
a) K397A;
b) K397D;
c) K397C;
d) K397Q ;
e) D425A;
f) D425N;
g) D425E;
h) D425K;
i) F427A;
j) K397+D425K双突变;
k) K395D+K397D+D425K+D426K四重突变;
1) K397D+D425K+F427A三重突变;
m) F427A+ΔD2L2双突变;
n) K397D+F427A+ΔD2L2三重突变;
o) K397D+D425K+F427A+ΔD2L2四重突变;
p) F427D;和
q) F427K。
5.一种疫苗组合物,其包含在药学上可接受的载体上的由两组分组成的孔形成A-B毒素的B组分或其片段,其中所述的B组分包含抑制其孔形成能力的突变。
6.如权利要求5所述的疫苗组合物,其中所述的B组分是炭疽保护性抗原。
7.如权利要求5所述的疫苗组合物,其中所述的B组分是经化学或物理方式灭活的。
8.一种预防哺乳动物中细菌感染的方法,所述的方法包括对所述哺乳动物施用含有包含在药学上可接受的载体上的,由两组分组成的孔形成A-B毒素的B组分或其片段的疫苗,其中,所述的B组分包含抑制其孔形成能力的突变。
9.一种治疗哺乳动物中细菌感染的方法,所述的方法包括对所述哺乳动物施用含有包含在药学上可接受的载体上的,由两组分组成的孔形成A-B毒素的B组分或其片段的疫苗,其中,所述的B组分包含抑制其孔形成能力的突变。
10.如权利要求8或9所述的方法,其中所述的疫苗与佐剂一起施用。
11.一种由两组分组成的孔形成A-B毒素的突变体B组分,其中,所述的突变体B组分包含抑制其孔形成能力的突变体,其中所述的突变体B组分抑制所述毒素天然存在的B组分的孔形成能力。
12.如权利要求11所述的突变体B组分,其中所述的突变体B组分是炭疽保护性抗原。
13.如权利要求12所述的突变体B组分,其具有与致命因子或水肿因子结合的能力。
14.如权利要求11所述的突变体B组分,其具有与所述天然存在的B组分竞争结合哺乳动物细胞表面受体的能力。
15.如权利要求11所述的突变体B组分,其具有与所述天然存在的B组分相结合的能力。
16.如权利要求11所述的突变体B组分,其具有与天然存在的B组分寡聚化以形成具有减弱的孔形成能力的复合物的能力。
17.如权利要求16所述的突变体B组分,其中,所述的复合物缺少孔形成能力。
18.如权利要求11所述的突变体B组分,其中所述的B组分具有与SEQ ID No.:21有至少80%同一性的氨基酸序列,并具有选自下述的突变:
a) K397D+D425K双突变;
b) ΔD2L2;
c) K395D+K397D+D425K+D426K四重突变;
d) D425K;
e) F427A;
f) K397D+D425K+F427A三重突变;
g) F427A+ΔD2L2双突变;
h) K397D+F427A+ΔD2L2三重突变;
i) K397D+D425K+F427A+ΔD2L2四重突变;
h) F427D;和
i) F427K。
19.如权利要求11所述的突变体B组分,其包含D2L2环的至少5个氨基酸的缺失。
20.一种在哺乳动物中预防细菌感染的方法,所述的方法包括对所述哺乳动物施用由两组分组成的孔形成A-B毒素的突变体B组分或其片段,其中所述的突变体B组分包含抑制其孔-形成能力的突变,其中所述的突变体B组分抑制所述毒素天然存在的B组分的孔形成能力。
21.一种在哺乳动物中治疗细菌感染的方法,所述的方法包括对所述哺乳动物施用由两组分组成的孔形成A-B毒素的突变体B组分或其片段,其中所述的突变体B组分包含抑制其孔-形成能力的突变,其中所述的突变体B组分抑制所述毒素天然存在的B组分的孔形成能力。
22.如权利要求8,9,20,或21所述的方法,其中所述的B组分或突变体B组分是炭疽保护性抗原,所述的细菌感染是炭疽感染。
23.如权利要求8,9,20,或21所述的方法,其进一步包括对所述哺乳动物施用与天然存在的B组分结合的抗体。
24.如权利要求8,9,20,或21所述的方法,其中所述的哺乳动物是人。
25.如权利要求24所述的方法,其中所述的哺乳动物已暴露于炭疽杆菌(B.anthracis)孢子。
26.一种纯化的抗体,其以比与所述毒素的突变体B组分结合更高的亲和力,与由两组分组成的孔形成A-B毒素的B组分特异性地结合,其中所述的突变体B组分包含抑制其孔形成能力的突变。
27.如权利要求26所述的抗体,其中,所述的突变体B组分抑制所述毒素天然存在的B组分的孔形成能力。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20180000P | 2000-05-04 | 2000-05-04 | |
US60/201,800 | 2000-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1440419A true CN1440419A (zh) | 2003-09-03 |
Family
ID=22747352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01812400A Pending CN1440419A (zh) | 2000-05-04 | 2001-05-04 | 治疗和预防细菌感染的化合物和方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7037503B2 (zh) |
EP (1) | EP1278764A4 (zh) |
JP (1) | JP2003531841A (zh) |
KR (1) | KR20030019366A (zh) |
CN (1) | CN1440419A (zh) |
AU (1) | AU2001261171A1 (zh) |
CA (1) | CA2407443A1 (zh) |
CZ (1) | CZ20023662A3 (zh) |
HU (1) | HUP0301658A2 (zh) |
IL (1) | IL152553A0 (zh) |
MX (1) | MXPA02010826A (zh) |
NO (1) | NO20025204L (zh) |
PL (1) | PL365453A1 (zh) |
WO (1) | WO2001082788A2 (zh) |
ZA (1) | ZA200208835B (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455673B1 (en) * | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
ATE360071T1 (de) | 2000-12-05 | 2007-05-15 | Wisconsin Alumni Res Found | Rezeptor für ein toxin aus bacillus anthracis |
US7763451B2 (en) | 2001-11-09 | 2010-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for preparing Bacillus anthracis protective antigen for use in vaccines |
JP2005511059A (ja) * | 2001-12-05 | 2005-04-28 | バートナガー ラケシュ | 非毒性炭疽ワクチンの調製のためのプロセス |
US20040258699A1 (en) * | 2002-02-11 | 2004-12-23 | Bowdish Katherine S. | Immunotherapeutics for biodefense |
WO2003076568A2 (en) * | 2002-02-11 | 2003-09-18 | Alexion Pharmaceuticals, Inc. | Immunotherapeutics for biodefense |
US7201912B2 (en) * | 2002-04-12 | 2007-04-10 | Emergent Biodefense Operation Lansing Inc. | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis |
US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
WO2004003139A2 (en) * | 2002-06-26 | 2004-01-08 | Human Genome Sciences, Inc. | Modified shine-dalgarno sequences and methods of use thereof |
EP1575505A4 (en) * | 2002-09-10 | 2007-01-24 | Vical Inc | CODON OPTIMIZATION-BASED POLYNUCLEOTIDE VACCINES AGAINST BACILLUS ANTHRACIS INFECTION |
AU2003304316A1 (en) * | 2002-11-08 | 2005-01-28 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
US7553930B2 (en) * | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
US20050221443A1 (en) * | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
US20050130892A1 (en) * | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
MXPA05008340A (es) * | 2003-02-06 | 2006-03-13 | Cerus Corp | Microbios de vida libre modificados, composiciones de vacuna y metodos de uso de los mismos. |
US7691393B2 (en) * | 2003-02-06 | 2010-04-06 | Anza Therapeutics, Inc. | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof |
US7695725B2 (en) * | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
US7842289B2 (en) * | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US20100003276A1 (en) * | 2004-12-07 | 2010-01-07 | Hermes Jeffery D | Methods for treating anthrax and inhibiting lethal factor |
WO2007008904A2 (en) * | 2005-07-08 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections |
AU2007259329A1 (en) * | 2006-05-12 | 2007-12-21 | Farris, Darise | Anthrax compositions and methods of use and production |
WO2009126355A2 (en) * | 2008-01-28 | 2009-10-15 | Baxter International, Inc. | Methods of increasing recombinant production of bacillus anthracis protective antigen |
US20110110968A1 (en) * | 2009-11-12 | 2011-05-12 | Stanley Goldman | Human optimized Bacillus anthracis protective antigen |
CN107022532B (zh) | 2011-04-22 | 2021-05-04 | 惠氏有限责任公司 | 涉及突变体难辨梭菌毒素的组合物及其方法 |
BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792458A (en) * | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
US5591631A (en) | 1993-02-12 | 1997-01-07 | The United States Of America As Represented By The Department Of Health And Human Services | Anthrax toxin fusion proteins, nucleic acid encoding same |
US5677274A (en) | 1993-02-12 | 1997-10-14 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Anthrax toxin fusion proteins and related methods |
US6455673B1 (en) * | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US5917017A (en) * | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US20030202989A1 (en) | 1995-12-13 | 2003-10-30 | R. John Collier | Use of toxin peptides and/or affinity handles for delivering compounds into cells |
GB9618107D0 (en) * | 1996-08-30 | 1996-10-09 | Secr Defence | Vaccine production |
WO1999042473A1 (en) | 1998-02-18 | 1999-08-26 | President And Fellows Of Harvard College | Inhibition of toxin translocation |
US6426231B1 (en) * | 1998-11-18 | 2002-07-30 | The Texas A&M University System | Analyte sensing mediated by adapter/carrier molecules |
US6413768B1 (en) * | 1998-12-02 | 2002-07-02 | University Of Maryland | Expression plasmids |
US6329156B1 (en) * | 1999-03-22 | 2001-12-11 | The Regents Of The University Of California | Method for screening inhibitors of the toxicity of Bacillus anthracis |
-
2001
- 2001-05-04 MX MXPA02010826A patent/MXPA02010826A/es unknown
- 2001-05-04 AU AU2001261171A patent/AU2001261171A1/en not_active Abandoned
- 2001-05-04 EP EP01935043A patent/EP1278764A4/en not_active Withdrawn
- 2001-05-04 CN CN01812400A patent/CN1440419A/zh active Pending
- 2001-05-04 US US09/848,909 patent/US7037503B2/en not_active Expired - Fee Related
- 2001-05-04 WO PCT/US2001/014372 patent/WO2001082788A2/en not_active Application Discontinuation
- 2001-05-04 HU HU0301658A patent/HUP0301658A2/hu unknown
- 2001-05-04 KR KR1020027014690A patent/KR20030019366A/ko not_active Application Discontinuation
- 2001-05-04 JP JP2001579671A patent/JP2003531841A/ja active Pending
- 2001-05-04 CZ CZ20023662A patent/CZ20023662A3/cs unknown
- 2001-05-04 PL PL01365453A patent/PL365453A1/xx unknown
- 2001-05-04 IL IL15255301A patent/IL152553A0/xx unknown
- 2001-05-04 CA CA002407443A patent/CA2407443A1/en not_active Abandoned
-
2002
- 2002-10-30 NO NO20025204A patent/NO20025204L/no not_active Application Discontinuation
- 2002-10-31 ZA ZA200208835A patent/ZA200208835B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20025204L (no) | 2002-12-16 |
MXPA02010826A (es) | 2006-03-09 |
CZ20023662A3 (cs) | 2003-04-16 |
WO2001082788A3 (en) | 2002-07-25 |
JP2003531841A (ja) | 2003-10-28 |
CA2407443A1 (en) | 2001-11-08 |
EP1278764A4 (en) | 2004-05-19 |
IL152553A0 (en) | 2003-05-29 |
AU2001261171A1 (en) | 2001-11-12 |
WO2001082788A2 (en) | 2001-11-08 |
HUP0301658A2 (hu) | 2003-08-28 |
ZA200208835B (en) | 2004-02-09 |
PL365453A1 (en) | 2005-01-10 |
EP1278764A2 (en) | 2003-01-29 |
US7037503B2 (en) | 2006-05-02 |
KR20030019366A (ko) | 2003-03-06 |
NO20025204D0 (no) | 2002-10-30 |
US20020039588A1 (en) | 2002-04-04 |
WO2001082788A9 (en) | 2002-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1440419A (zh) | 治疗和预防细菌感染的化合物和方法 | |
CN1117149C (zh) | 用于免疫治疗和诊断结核病的化合物和方法 | |
CN1284965A (zh) | 脑膜炎奈瑟氏球菌的新表面蛋白 | |
CN1145697C (zh) | 治疗和诊断组合物 | |
CN1437653A (zh) | 抗原多肽 | |
CN1222618C (zh) | 卡他摩拉克菌外膜蛋白-106多肽及其基因序列和用途 | |
CN1214114C (zh) | 可活化的重组神经毒素 | |
CN1279717A (zh) | 肺炎衣原体的基因组序列和其多肽、片段以及其用途特别是用于诊断、预防和治疗感染 | |
CN1200146A (zh) | 用于结核病诊断的化合物和方法 | |
CN1251611A (zh) | 粘膜炎莫拉菌的uspa1和uspa2抗原 | |
CN1433471A (zh) | 85kgDa奈瑟球菌的抗原 | |
CN1184505A (zh) | 鼠疫疫苗 | |
CN1484702A (zh) | 苏云金芽孢杆菌杀昆虫蛋白质 | |
CN1235555A (zh) | 治疗和诊断分枝杆菌感染的化合物和方法 | |
CN1263436A (zh) | 在螺杆菌属基因组中鉴定编码新型螺杆菌属多肽的多核苷酸 | |
CN1556857A (zh) | 呼吸道合胞病毒(rsv)g蛋白的新肽及其在疫苗中的应用 | |
CN1298848C (zh) | 具有减弱的蛋白酶活性的嗜血杆菌Hin47类似物 | |
CN1212016A (zh) | 重组的核糖核酸酶蛋白质 | |
CN1427892A (zh) | 毒力基因、蛋白及其用途 | |
CN1261403A (zh) | 新的肺炎衣原体表面蛋白 | |
CN1283120A (zh) | Cd8作为细胞免疫系统的抑制剂 | |
CN1235513A (zh) | 与幽门螺杆菌及其疫苗组合物有关的核酸和氨基酸序列 | |
CN1198918C (zh) | 减毒的活胸膜肺炎放线杆菌 | |
CN1391612A (zh) | 来自嗜热棒状杆菌的氨基酸生物合成途径的抗热酶的基因 | |
CN1246799A (zh) | 关于幽门螺杆菌的核酸序列和氨基酸序列及其疫苗组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |